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Summary of findings {#CD012118-sec1-0001}
===================

Summary of findings for the main comparisonRifampicin combined with streptomycin compared with surgery alone for Buruli ulcer**Rifampicin combined with streptomycin compared with surgery alone for Buruli ulcerPatient or population:** people with Buruli ulcer, non‐ulcerated lesions measuring less than 10 cm in diameter, aged 15 years or older\
**Settings:** Ghana\
**Intervention:** rifampicin combined with streptomycin\
**Comparison:** surgery alone**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)Number of participants (studies)Certainty of the evidence (GRADE)CommentsAssumed riskCorresponding riskSurgery aloneSurgery plus rifampicin combined with streptomycin**Recurrence,\
12 months**20 per 1002.4 per 100** (\< 1 to 50)**RR 0.12** (0.01 to 2.51)21 participants (1 trial)⊕⊝⊝⊝ VERY LOW^a,b^\
due to risk of bias and imprecisionWe do not know if the treatment reduces recurrence.\*The basis for the **assumed risk** (for example, the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **Abbreviations:** CI: confidence interval; RR: risk ratioGRADE Working Group grades of evidence **High certainty:** further research is very unlikely to change our confidence in the estimate of effect. **Moderate certainty:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low certainty:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low certainty:** we are very uncertain about the estimate.[^2]

Summary of findings 2Rifampicin with clarithromycin compared with rifampicin with streptomycin in the consolidation phase for Buruli ulcer**Rifampicin with clarithromycin compared with rifampicin with streptomycin in the consolidation phase for Buruli ulcerPatient or population:** people with Buruli ulcer, early lesions measuring less than 10 cm in diameter, aged 5 years or older\
**Settings:** Ghana\
**Intervention:** rifampicin with streptomycin, followed by rifampicin with clarithromycin after 4 weeks\
**Comparison:** rifampicin with streptomycin continued**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)Number of participants (studies)Certainty of the evidence (GRADE)CommentsAssumed riskCorresponding riskStreptomycin continuedClarithromycin substitute**Cure^a^96 per 10090 per 100\
(84 to 99)RR 0.94\
(0.87 to 1.03)151\
(1 trial)⊕⊕⊝⊝ LOW^b^\
due to imprecisionWe do not know if the treatment is superior to the control.\*The basis for the **assumed risk** (for example, the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **Abbreviations:** CI: confidence interval; RR: risk ratioGRADE Working Group grades of evidence **High certainty:** further research is very unlikely to change our confidence in the estimate of effect. **Moderate certainty:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low certainty:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low certainty:** we are very uncertain about the estimate.[^3]

Background {#CD012118-sec1-0002}
==========

Buruli ulcer is a necrotizing cutaneous infection caused by infection with *Mycobacterium ulcerans* bacteria, which is categorized as a non‐tuberculous mycobacterium. It is an emerging disease first described by [@CD012118-bbs2-0104] in six Australian patients. The disease was named after Buruli County in Uganda, where a large number of cases were reported in the 1960s ([@CD012118-bbs2-0080]; [@CD012118-bbs2-0123]). Since then, the number of Buruli ulcer cases has gradually increased ([@CD012118-bbs2-0139]). In spite of this, the disease is still poorly understood, especially its transmission mode. Several studies have demonstrated that the infection is linked to aquatic environments ([@CD012118-bbs2-0050]; [@CD012118-bbs2-0078]; [@CD012118-bbs2-0105]; [@CD012118-bbs2-0083]; [@CD012118-bbs2-0095]). However, the natural reservoir and mode of transmission of the infection remain a mystery and may differ between endemic foci worldwide ([@CD012118-bbs2-0108]).

Currently, over 33 countries worldwide report cases of Buruli ulcer, mainly in people living in tropical and subtropical regions ([@CD012118-bbs2-0135]). About 2000 to 5000 new cases are reported annually, mostly in countries in West and Central Africa ([@CD012118-bbs2-0135]). Most people who are infected in these countries are children aged under 15 years, living in remote rural areas with limited access to health facilities ([@CD012118-bbs2-0107]; [@CD012118-bbs2-0076]; [@CD012118-bbs2-0058]; [@CD012118-bbs2-0132]). Other important foci include Australia ([@CD012118-bbs2-0077]; [@CD012118-bbs2-0121]), French Guiana ([@CD012118-bbs2-0081]), Papua New Guinea ([@CD012118-bbs2-0093]; [@CD012118-bbs2-0096]), and more recently, Japan ([@CD012118-bbs2-0138]). In addition, a number of cases have been reported in international travellers from non‐endemic areas, including North America and European countries ([@CD012118-bbs2-0126]; [@CD012118-bbs2-0087]; [@CD012118-bbs2-0079]; [@CD012118-bbs2-0117]; [@CD012118-bbs2-0086]; [@CD012118-bbs2-0084]; [@CD012118-bbs2-0085]). Nevertheless, awareness and knowledge of the disease among health practitioners and the community are still lacking, hence the possibility of hidden unreported cases ([@CD012118-bbs2-0135]). In endemic countries, poor health infrastructure and geographical challenges also contribute to the underreporting of cases ([@CD012118-bbs2-0135]). If left undiagnosed and untreated, the disease can lead to lifelong disfigurement and disabilities, which impact greatly on the lives of those affected, especially in resource‐poor conditions where most of these people reside.

Description of the condition {#CD012118-sec2-0001}
----------------------------

The subcutaneous tissue is the primary site of infection by *M ulcerans* ([@CD012118-bbs2-0124]). The bacteria produce mycolactone, an immunomodulatory macrolide toxin, which is the main pathogenic factor of the disease. This toxin induces tissue necrosis, particularly in subcutaneous fat ([@CD012118-bbs2-0125]). Initially, the disease presents as a nodule, papule, plaque (firm, painless, and raised lesion, which is larger than a papule), or oedema, which when left alone eventually breaks open the skin and forms an ulcer. A typical ulcer usually has necrotic slough, undermined edges, and is often painless (unless complicated with a secondary infection) ([@CD012118-bbs2-0124]). *M ulcerans* infection often affects the upper and lower limbs and the face, as these are exposed body areas. It can progress sideways to become a larger lesion involving the joints, as well as deeper into the tissue and cause osteomyelitis in some cases. However, it is rare for the infection to disseminate systemically and cause death ([@CD012118-bbs2-0118]). If death occurs, it is usually related to sepsis from a secondary infection or tetanus ([@CD012118-bbs2-0124]).

The World Health Organization (WHO) has classified Burui ulcer lesions into three groups according to important clinical features and size, with implications for their management ([@CD012118-bbs2-0134]). Category I is a small, early lesion less than 5 cm in diameter; category II is a lesion of 5 to 15 cm in diameter; and category III is a lesion more than 15 cm in diameter, multiple lesions, or lesion(s) at a critical site (eye, breast, genitalia) and osteomyelitis ([@CD012118-bbs2-0134]). Some people experience spontaneous healing during the course of the disease, but the mechanism for this is unclear ([@CD012118-bbs2-0094]; [@CD012118-bbs2-0089]). In severe cases, lifelong sequelae may develop. [@CD012118-bbs2-0128] reported that among their 1043 laboratory‐confirmed cases of Buruli ulcers in Benin, 229 people (22%) developed permanent functional impairment one year after their treatment.

The association between Buruli ulcer and HIV/AIDS is not yet clear; there have been some reports on the possible increased rate of infection and severity in those with HIV/AIDS ([@CD012118-bbs2-0129]; [@CD012118-bbs2-0122]).

### Diagnosis {#CD012118-sec3-0001}

Buruli ulcer possesses characteristic clinical features, and hence clinical diagnosis is possible to a certain extent in endemic areas. However, for definitive diagnosis, laboratory microbiological methods are required, including Ziehl‐Neelsen (ZN) staining for detecting acid‐fast bacilli (AFB), in vitro culture, polymerase chain reaction (PCR) assay targeting genomic region IS2404, and histopathology. Findings from at least one of these laboratory microbiological methods should be suggestive of Buruli ulcer to confirm diagnosis ([@CD012118-bbs2-0136]). Samples can be obtained by fine‐needle aspiration from a non‐ulcerative lesion, and purulent discharge fluid or swab from the undermined wound edge of an ulcerative lesion. Skin biopsy is a reliable sample source, but this can only be performed with adequate skills, tools, and hygienic environment, which may be limited in places where Buruli ulcer is endemic. The WHO is currently promoting PCR confirmation for at least 70% of all reported cases of Buruli ulcer ([@CD012118-bbs2-0136]).

Description of the intervention {#CD012118-sec2-0002}
-------------------------------

Since the first description of the disease in 1948, the standard treatment for Buruli ulcers was extensive surgical debridement of affected skin and surrounding tissue, with or without subsequent skin grafting ([@CD012118-bbs2-0082]; [@CD012118-bbs2-0125]). However, surgical treatment alone was insufficient to eradicate all the *M ulcerans* bacteria, and recurrence was common. Although the recurrence rate varied between studies, it was reported to be from 6% to 32% ([@CD012118-bbs2-0075]; [@CD012118-bbs2-0042]; [@CD012118-bbs2-0036]; [@CD012118-bbs2-0099]; [@CD012118-bbs2-0113]). Moreover, surgery is available only to a small fraction of the population in the most affected areas of low‐ and middle‐income countries due to limited hospital capacities, and difficulties relating to accessibility and cost ([@CD012118-bbs2-0133]). Lesion site is another challenge. If the ulcer involves the face, joints, or other important body parts, which is not a rare occurrence in people with Buruli ulcer, surgical excision may cause disfiguring or disabling consequences ([@CD012118-bbs2-0118]). For these reasons, there has been a continuous exploration for other medical approaches that can effectively cure Buruli ulcer, including topical treatments using nitrogen oxide ([@CD012118-bbs2-0114]; [@CD012118-bbs2-0115]), phenytoin powder ([@CD012118-bbs2-0101]), local heat treatment ([@CD012118-bbs2-0109]; [@CD012118-bbs2-0103]; [@CD012118-bbs2-0097]; [@CD012118-bbs2-0130]), hyperbaric oxygen therapy ([@CD012118-bbs2-0102]; [@CD012118-bbs2-0103]), and antibiotic treatments ([@CD012118-bbs2-0133]; [@CD012118-bbs2-0134]; [@CD012118-bbs2-0137]).

Several trials of different antibiotic treatments have been conducted, including clofazimine and sulfamethoxazole/trimethoprim ([@CD012118-bbs2-0017]; [@CD012118-bbs2-0010]), but results of these monotherapies were disappointing. Rifampicin, when used alone, caused the development of a rifampicin‐resistant *M ulcerans* strain in a mice model, suggesting that it should never be used as monotherapy in people, as in people with tuberculosis (TB) or leprosy ([@CD012118-bbs2-0106]). In 2004, based on in vitro findings and pilot clinical studies, the WHO introduced a combination of rifampicin (10 mg/kg orally once daily) and streptomycin (15 mg/kg intramuscularly once daily) for eight weeks (critical base drugs in TB) as a first‐line therapy for people with Buruli ulcer ([@CD012118-bbs2-0133]), which has greatly simplified the treatment and delivery of care for those affected. Nevertheless, surgical treatment adjunctive to antibiotics still plays an important role in Buruli ulcer management, especially for people with severe, large ulcers. The WHO recommends surgical intervention for category III cases and some category II cases, following careful assessment of the efficacy of the antibiotic treatment. In Buruli ulcer, surgical debridement is performed extensively with a wide margin, as mycolactone exists in the subcutaneous fat tissue beyond the wound edges.

Despite antibiotic treatment being effective to an extent, some concerns remain with the current recommended regimen. Streptomycin requires intramuscular injection, which is invasive, therefore patient acceptance and adherence are affected. It is also operationally demanding and of limited availability to people living in remote areas where Buruli ulcer is most endemic, especially rural Africa. Additionally, in these areas, administration of drugs by injection carries the risk of HIV transmission. Potential adverse effects from streptomycin, including ototoxicity and nephrotoxicity, are another concern. There is also concern about encouraging the development of multidrug‐resistant TB, as both rifampicin and streptomycin are also effective antituberculosis drugs. Active TB would need to be confidently ruled out before treatment, and considering that this judgement may not always be completely accurate, there may be substantial consequences for the future of TB treatment. The search for a fully orally administered treatment regimen to replace rifampicin and streptomycin combination for the treatment of Buruli ulcer is thus ongoing. Several options have already been explored as replacements for the curative rifampicin and streptomycin combination, including: rifampicin and dapsone ([@CD012118-bbs2-0008]), rifampicin and clarithromycin ([@CD012118-bbs2-0005]; [@CD012118-bbs2-0007]; [@CD012118-bbs2-0016]; [@CD012118-bbs2-0011]), rifampicin and ciprofloxacin ([@CD012118-bbs2-0014]; [@CD012118-bbs2-0011]), and rifampicin, levofloxacin, and clarithromycin ([@CD012118-bbs2-0120]).

To date, evaluating the efficacy of treatments for Buruli ulcer has been challenging for several clinical and biological reasons. Firstly, there have been cases in which deterioration was observed during the course of treatment, which are now defined as paradoxical reactions. This phenomenon is now understood to be the result of antibiotic suppression of mycolactone synthesis, leading to the reversal of host immune response to*M ulcerans* ([@CD012118-bbs2-0054]). Paradoxical reactions may occur at the same site as the initial lesion, or at other sites. When it is at the same site, it is especially difficult to differentiate paradoxical reactions from recurrences; this identification largely influences the clinical decision. The WHO defines recurrences as new and culture‐confirmed lesions occurring more than three months after completion of antibiotic treatment ([@CD012118-bbs2-0134]). However, the two conditions cannot be fully differentiated based on this definition alone. Since paradoxical reactions have only recently been documented, some past data on recurrences may have mistakenly included paradoxical reactions. Secondly, microbiological cure and clinical cure are not always the same. In other words, even though *M ulcerans* was successfully eliminated from the lesion site with antibiotic treatment (microbiological cure), this does not correspond to clinical cure if the patient has already manifested an ulcer. Moreover, in such ulcerated cases, methods used in wound care would also modify the healing process; this is another challenge in correctly evaluating antimicrobial treatment efficacy in people with Buruli ulcer. Selection of wound care methods is often dependent upon daily practice and resource availability. [@CD012118-bbs2-0127] documented that there was a wide diversity in local wound care methods practiced by health practitioners/healthcare givers in Ghana and Benin. Due to these atypical clinical features and medical practices related to the disease, it has been difficult to develop a clear case definition for cure. Many studies evaluating treatment efficacy in Buruli ulcer disease have used complete epithelialization, [@CD012118-bbs2-0006]; [@CD012118-bbs2-0120], or reduction in wound size, [@CD012118-bbs2-0009]; [@CD012118-bbs2-0005]; [@CD012118-bbs2-0120], as their definition of cure (clinical cure), while a few studies have also used microbiological cure as their case definition of cure, employing laboratory methods ([@CD012118-bbs2-0009]; [@CD012118-bbs2-0018]).

How the intervention might work {#CD012118-sec2-0003}
-------------------------------

As Buruli ulcer is a mycobacterial disease and with growing experience in its management, antibiotic drugs are now an essential part of its treatment ([@CD012118-bbs2-0134]; [@CD012118-bbs2-0139]). After the introduction of antibiotic drugs for the treatment of Buruli ulcer by the WHO in 2004, recurrence rates reportedly decreased substantially to 0% to 2%, and the need for surgical intervention has diminished ([@CD012118-bbs2-0006]; [@CD012118-bbs2-0005]; [@CD012118-bbs2-0018]). With this simplified treatment and delivery of care, the quality of life of patients has increased not only during treatment, but also after treatment as use of antibiotic drugs has played a role in decreasing the number of those affected by the disease who are left with disabilities and disfigurements ([@CD012118-bbs2-0046]). In West Africa, where over 40% of those affected are children under 15 years of age, better treatment further provides better opportunity for education, and thus a better future ([@CD012118-bbs2-0002]; [@CD012118-bbs2-0134]). The use of antibiotic drugs has also decreased the socioeconomic impact on families, as the cost of treatment of surgeries and hospitalization is far beyond the means of those most severely affected ([@CD012118-bbs2-0076]; [@CD012118-bbs2-0091]; [@CD012118-bbs2-0002]).

Why it is important to do this review {#CD012118-sec2-0004}
-------------------------------------

No systematic review of the literature on Buruli ulcer has previously been performed. A review of the efficacy of daily administration of rifampicin and streptomycin in the treatment of early‐stage Buruli ulcer including data from 2005 to 2012 was published in 2013 ([@CD012118-bbs2-0131]). In that review, evidence of diagnostic accuracy and ascertainment of cure was not clear. Also, the review did not include treatment modalities other than rifampicin and streptomycin. In this Cochrane Review, we aimed to assess the effects of antibiotic treatment with or without surgical intervention (debridement, skin grafting, etc.) for people with Buruli ulcer. As the search for more efficacious and/or convenient treatment modalities continues, it was an appropriate time to evaluate and summarize the evidence on current treatment options.

Objectives {#CD012118-sec1-0003}
==========

To summarize the evidence of drug treatments for treating Buruli ulcer.

Methods {#CD012118-sec1-0004}
=======

Criteria for considering studies for this review {#CD012118-sec2-0005}
------------------------------------------------

### Types of studies {#CD012118-sec3-0002}

Randomized controlled clinical trials (RCTs) and prospective observational studies.

### Types of participants {#CD012118-sec3-0003}

We included participants diagnosed as having Buruli ulcer due to the presence of a suggestive lesion and any one of the following:

a culture of *M ulcerans* from the lesion;a positive IS2404 dry‐reagent‐based PCR from a swab or biopsy of the lesion;histopathological finding indicative of *M ulcerans* infection (for example, necrotic granuloma, presence of AFB), irrespective of age.

### Types of interventions {#CD012118-sec3-0004}

We included studies that compared:

antibiotic therapy to placebo or alternative therapy such as surgery;different antibiotic regimens.

We also included prospective observational studies that evaluated different antibiotic regimens with or without surgery.

### Types of outcome measures {#CD012118-sec3-0005}

#### Primary outcomes {#CD012118-sec4-0001}

Cure: healing of skin lesions without recurrence at 12 months or longer.Probable cure: healing of skin lesions with follow‐up to 12 months.Possible cure: healing of skin lesions at follow‐up.

#### Secondary outcomes {#CD012118-sec4-0002}

Surgery.Healing time needed for wound closure.Reduction in ulcer size.Recurrence of skin lesion(s) after healing.Adverse effects.Paradoxical reactions.

Search methods for identification of studies {#CD012118-sec2-0006}
--------------------------------------------

We attempted to identify all potential studies regardless of language or publication status (published, unpublished, in press, and in progress).

### Electronic searches {#CD012118-sec3-0006}

We searched the following databases using the search terms and strategy described in [Appendix 1](Appendix 1): the Cochrane Infectious Diseases Group Specialized Register; the Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library (Issue 11, 2017); MEDLINE (PubMed; from 1966); Embase (Ovid; from 1947); and LILACS (Latin American and Caribbean Health Sciences Literature; BIREME) (from 1982). All searches were conducted on 19 December 2017. We also searched the US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov ([clinicaltrials.gov](clinicaltrials.gov)) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) ([www.who.int/ictrp/search/en/](www.who.int/ictrp/search/en/)) up to 19 December 2017 using "Buruli ulcer\*" as a search term.

### Searching other resources {#CD012118-sec3-0007}

We reviewed the reference lists of all included studies. We also contacted leading researchers in this topic area to identify any unpublished data.

Data collection and analysis {#CD012118-sec2-0007}
----------------------------

### Selection of studies {#CD012118-sec3-0008}

Vittoria Lutje, the Cochrane Infectious Diseases Group (CIDG) Information Specialist, searched the literature and retrieved studies using the search strategy outlined in [Appendix 1](#CD012118-sec2-0015){ref-type="app"}. In the initial stage of selection, two review authors (Rie Roselyne Yotsu (RRY) and Marty Richardson (MR)) independently screened the abstracts of studies retrieved by the search to identify those that met the inclusion criteria. We retrieved the full‐text articles of published or unpublished potentially relevant study reports for further assessment. Rie Roselyne Yotsu or Marty Richardson contacted the study authors for further details regarding study methodology if eligibility was unclear. A third review author (Norihisa Ishii (NI)) was consulted when there was a difference of opinion between RRY and MR. If there was still disagreement between the review authors, we consulted one of the CIDG Co‐ordinating Editors to reach a consensus. We examined study reports to ensure that we included multiple publications from the same study only once.

### Data extraction and management {#CD012118-sec3-0009}

Two review authors (RRY and MR) extracted and summarized data from the included studies on standardized data extraction forms. Any differences of opinion were resolved through discussion. If important data were missing from the included studies, we contacted the study authors for further information.

We extracted the number of participants randomized and the number of participants followed up in each treatment arm, with a list of each study\'s inclusion and exclusion criteria, a description of the intervention(s), and primary and secondary outcome measures. The data extraction form also included baseline characteristics of participants in the control group such as age, sex, stage of lesions, ulcer size, WHO category, diagnostic results, healing time, side effects, outcome, post‐treatment surgery, and recurrence. Rie Roselyne Yotsu entered the data into Review Manager 5 ([@CD012118-bbs2-0116]).

For dichotomous outcomes, we extracted the number of participants experiencing the event and the number of participants in each treatment group. For continuous outcomes, we extracted arithmetic means, standard deviations, and the numbers of participants for each treatment group.

### Assessment of risk of bias in included studies {#CD012118-sec3-0010}

All review authors (RRY, MR, and NI) independently assessed the risk of bias for each included study. We assessed RCTs using the Cochrane 'Risk of bias\' assessment tool with seven domains of bias including: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other potential sources of bias ([@CD012118-bbs2-0092]). We assessed prospective observational studies in accordance with methods adopted from 'A Cochrane Risk of Bias Assessment Tool: for Non‐Randomized Studies of Interventions\' (ACROBAT‐NRSI) ([@CD012118-bbs2-0119]). We assessed five domains of bias including: selection of participants into the study, measurement of outcomes, incomplete outcome data, selective reporting, and other potential sources of bias.

We assigned a judgement of either 'high\', 'low\', or 'unclear\' risk of bias for each component. We chose 'unclear\' either when the available information was inadequate to judge or when it was neither 'high\' nor 'low\'. Any discrepancies regarding 'Risk of bias\' analysis results were resolved through discussion. We consulted one of the CIDG Co‐ordinating Editors if necessary. We presented the findings in a 'Risk of bias\' table, and produced figures to summarize the risk of bias across included studies. For domains that did not pertain to the study design, we assigned 'unclear risk of bias\' for RCTs and 'low risk of bias\' for prospective observational studies so that all studies could be handled in a single 'Risk of bias\' graph and summary figure. We also labelled the study name and the domains with the study design in order to enable differentiation between the two study designs.

We further assessed the certainty of the evidence using the GRADE approach for any RCTs for which we could apply this method ([@CD012118-bbs2-0098]). We used GRADEpro GDT software to construct a 'Summary of findings\' table ([@CD012118-bbs2-0090]).

### Measures of treatment effect {#CD012118-sec3-0011}

For RCTs using dichotomous outcomes, we presented the effect of treatment within studies as the risk ratio (RR) with corresponding 95% confidence interval (CI).

### Unit of analysis issues {#CD012118-sec3-0012}

Had we identified studies for inclusion that had multiple intervention arms, we would have included data from these studies by either combining treatment arms, or by splitting the control group so that participants would only be included in the meta‐analysis once.

### Dealing with missing data {#CD012118-sec3-0013}

In the case of missing data, we attempted to contact the study authors to request the missing information. If the study authors did not collect or assess the needed data as part of their study, or if we received no response, we analysed the available data only using a complete‐case analysis.

### Assessment of heterogeneity {#CD012118-sec3-0014}

Had we performed meta‐analyses in this review, we would have inspected forest plots visually to assess whether statistical heterogeneity was present. We would have deemed CIs that did not overlap as indicating statistical heterogeneity.

### Assessment of reporting biases {#CD012118-sec3-0015}

We planned to assess reporting bias by using funnel plots, however we did not create these as we did not perform any meta‐analyses in this review.

### Data synthesis {#CD012118-sec3-0016}

We compared studies in terms of combination of antibiotics and duration, whether adjunctive surgery was performed or not, and lesion size/types in order to determine whether it was possible, and appropriate, to perform meta‐analyses. We consequently decided that it was not possible to perform meta‐analyses due to the small number of studies with the same intervention, different inclusion criteria (for example, some studies only included small lesions while others included large lesions; some studies only included ulcerated lesions while others included non‐ulcerated lesions), and different follow‐up/assessment time points. We presented the key characteristics of included studies alongside outcome data in tables, and discussed the results of the included studies narratively.

We will refer to the methods described in the protocol should we need to conduct analyses in future updates.

### Subgroup analysis and investigation of heterogeneity {#CD012118-sec3-0017}

Had we detected substantial heterogeneity in meta‐analyses, we would have explored the possible causes of the heterogeneity by performing subgroup analyses. Subgroups for investigation included lesion sizes, clinical lesions (papule, nodule, plaque, oedema, and ulcer), and surgical intervention.

### Sensitivity analysis {#CD012118-sec3-0018}

We did not perform sensitivity analyses as we did not perform any meta‐analyses in this review.

Results {#CD012118-sec1-0005}
=======

Description of studies {#CD012118-sec2-0008}
----------------------

### Results of the search {#CD012118-sec3-0019}

We conducted literature searches up to 19 December 2017 and identified 548 titles ([Figure 1](#CD012118-fig-0001){ref-type="fig"}). While searching for additional information on [@CD012118-bbs2-0028], we identified one study through its conference proceeding ([@CD012118-bbs2-0004]), and one study through ongoing trials ([@CD012118-bbs2-0003]). Two review authors (RRY and MR) closely examined 75 full‐text articles. We contacted the technical team at the WHO for possible unpublished studies; there were none other than those we identified. We identified two ongoing trials on US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov ([@CD012118-bbs2-0073]; [@CD012118-bbs2-0074]).Figure 1Study flow diagram.

We identified six RCTs and 15 prospective observational studies that met the inclusion criteria. Two review authors (RRY and MR) independently extracted data for these studies.

### Included studies {#CD012118-sec3-0020}

#### Study design {#CD012118-sec4-0003}

Six articles reported a total of five RCTs. The BURULICO study was reported in two different articles with different outcomes ([@CD012118-bbs2-0110]; [@CD012118-bbs2-0100]; see [@CD012118-bbs2-0005]).

A total of 15 articles reported prospective observational studies. Five articles were from the same Australian group using the data of Buruli ulcer patients from their registry that they had started collecting in January 1998 ([@CD012118-bbs2-0111]; [@CD012118-bbs2-0014]; [@CD012118-bbs2-0088]; [@CD012118-bbs2-0015]; [@CD012118-bbs2-0011]), and evaluated a number of different combinations of antibiotics. We identified two sets of articles reporting data for the same groups of participants at different time points ([@CD012118-bbs2-0088] and [@CD012118-bbs2-0011]; [@CD012118-bbs2-0111] and [@CD012118-bbs2-0014]), therefore we extracted data from only the more recent papers ([@CD012118-bbs2-0014]; [@CD012118-bbs2-0011]). Some participants in [@CD012118-bbs2-0014], [@CD012118-bbs2-0015], and [@CD012118-bbs2-0011] may be included in more than one study, as they were from the same registry. [@CD012118-bbs2-0003] combined participants of the [@CD012118-bbs2-0005] and the ongoing [@CD012118-bbs2-0073] trial, therefore there is overlap of participants. However, [@CD012118-bbs2-0003] measured an outcome (paradoxical reactions) that was not an outcome measure of the original RCTs. We counted this study as an independent, prospective observational study.

We henceforth describe results of the qualitative synthesis of five RCTs and 13 prospective observational studies.

#### Interventions and comparisons {#CD012118-sec4-0004}

##### Randomized controlled trials {#CD012118-sec5-0001}

The included RCTs evaluated the following.

Monotherapy in comparison to placebo, with surgery when indicated: clofazimine in one trial ([@CD012118-bbs2-0017]), and sulfamethoxazole/trimethoprim in a second trial ([@CD012118-bbs2-0010]).Combination therapy:rifampicin + streptomycin before surgery with different lengths of treatment (varying from two to 12 weeks), in comparison to surgery alone ([@CD012118-bbs2-0009]);rifampicin + streptomycin for four weeks followed by rifampicin + clarithromycin for four weeks in comparison to rifampicin + streptomycin for eight weeks, with surgery when indicated ([@CD012118-bbs2-0005]);rifampicin + dapsone for eight weeks in comparison to no treatment, with no surgery in either arm ([@CD012118-bbs2-0008]).

##### Prospective observational studies {#CD012118-sec5-0002}

Two studies evaluated different treatment regimens in multiple treatment arms ([@CD012118-bbs2-0014]; [@CD012118-bbs2-0011]). All of the other prospective observational studies were single‐arm studies. Prospective observational studies evaluated the following.

Monotherapy with clofazimine for one to four weeks before surgery ([@CD012118-bbs2-0013]).Combination therapy with rifampicin + streptomycin for:12 weeks with surgery at week 4 ([@CD012118-bbs2-0012]);eight weeks with surgery when indicated ([@CD012118-bbs2-0006]; [@CD012118-bbs2-0018]; [@CD012118-bbs2-0001]; [@CD012118-bbs2-0004]);eight weeks with surgery ([@CD012118-bbs2-0002]).Combination therapy with rifampicin + clarithromycin:rifampicin + clarithromycin for eight weeks, with surgery when indicated ([@CD012118-bbs2-0007]);rifampicin + streptomycin for two weeks followed by rifampicin + clarithromycin for six weeks, with surgery when indicated ([@CD012118-bbs2-0016]).Other combination therapy:rifampicin + either ciprofloxacin, clarithromycin, or moxifloxacin, with no surgery or with limited debridement ([@CD012118-bbs2-0011]);rifampicin + ciprofloxacin, rifampicin + clarithromycin, rifampicin + clarithromycin + ethambutol, ciprofloxacin + clarithromycin, rifampicin + moxifloxacin, clarithromycin + ethambutol, rifampicin + ethambutol + amikacin, or clarithromycin only, with surgery in all cases, in comparison to surgery alone ([@CD012118-bbs2-0014]);single or combination administration of rifampicin, ciprofloxacin, clarithromycin, ethambutol, amikacin, and/or moxifloxacin, with surgery when indicated ([@CD012118-bbs2-0015]);either rifampicin + streptomycin for eight weeks or rifampicin + streptomycin for four weeks followed by rifampicin + clarithromycin for four weeks, with surgery when indicated ([@CD012118-bbs2-0003]).

#### Location and participants {#CD012118-sec4-0005}

All studies were conducted in areas with high Buruli ulcer endemicity: of the RCTs, three were conducted in Ghana and one in Côte d\'Ivoire and in Uganda; of the prospective observational studies, four were conducted in Ghana, three in Australia, two in Benin, one in Uganda, one in Democratic Republic of Congo, and one in Togo. [@CD012118-bbs2-0003] was a joint study between Ghana and Benin.

Some studies set inclusion criteria for age and lesion type or size given in diameter. Of the RCTs, the [@CD012118-bbs2-0005] recruited participants over five years with lesion size less than 10 cm; [@CD012118-bbs2-0009] recruited participants over 15 years with lesion size less than 10 cm; and [@CD012118-bbs2-0008] recruited participants over four years with ulcers. Of the prospective observational studies, [@CD012118-bbs2-0007] recruited participants over five years with lesion size less than 10 cm; [@CD012118-bbs2-0016] recruited participants over five years with lesion size less than 15 cm; [@CD012118-bbs2-0012] recruited participants between three and 75 years with lesion size larger than 10 cm; and the [@CD012118-bbs2-0073] trial (a part of [@CD012118-bbs2-0003]) recruited participants over three years of age. All other included studies recruited all age groups and lesion sizes.

Three RCTs, [@CD012118-bbs2-0010]; [@CD012118-bbs2-0009]; [@CD012118-bbs2-0005], and 10 prospective observational studies, [@CD012118-bbs2-0018]; [@CD012118-bbs2-0002]; [@CD012118-bbs2-0007]; [@CD012118-bbs2-0014]; [@CD012118-bbs2-0001]; [@CD012118-bbs2-0015]; [@CD012118-bbs2-0016]; [@CD012118-bbs2-0004]; [@CD012118-bbs2-0003]; [@CD012118-bbs2-0011], had laboratory confirmation as part of their inclusion criteria. The remaining included studies did not have laboratory confirmation as an inclusion criterion.

#### Outcomes and length of follow‐up {#CD012118-sec4-0006}

Outcomes in the RCTs varied. One trial measured \"cure\" ([@CD012118-bbs2-0005]), and one trial measured \"possible cure\" ([@CD012118-bbs2-0017]). Both trials also measured healing time ([@CD012118-bbs2-0017]; [@CD012118-bbs2-0005]). Otherwise, change in ulcer size was investigated in three trials ([@CD012118-bbs2-0010]; [@CD012118-bbs2-0008]; [@CD012118-bbs2-0009]), recurrence in three trials ([@CD012118-bbs2-0017]; [@CD012118-bbs2-0009]; [@CD012118-bbs2-0005]), and adverse effects in three trials ([@CD012118-bbs2-0008]; [@CD012118-bbs2-0009]; [@CD012118-bbs2-0005]).

Of the prospective observational studies, seven studies measured \"cure\" ([@CD012118-bbs2-0060]; [@CD012118-bbs2-0012]; [@CD012118-bbs2-0018]; [@CD012118-bbs2-0002]; [@CD012118-bbs2-0007]; [@CD012118-bbs2-0014]; [@CD012118-bbs2-0011]); one study measured \"probable cure\" ([@CD012118-bbs2-0006]); and three studies measured \"possible cure\" ([@CD012118-bbs2-0013]; [@CD012118-bbs2-0001]; [@CD012118-bbs2-0004]). Healing time was investigated in five studies ([@CD012118-bbs2-0018]; [@CD012118-bbs2-0007]; [@CD012118-bbs2-0016]; [@CD012118-bbs2-0004]; [@CD012118-bbs2-0011]), change in ulcer size in one ([@CD012118-bbs2-0018]), recurrence in eight ([@CD012118-bbs2-0006]; [@CD012118-bbs2-0012]; [@CD012118-bbs2-0018]; [@CD012118-bbs2-0002]; [@CD012118-bbs2-0007]; [@CD012118-bbs2-0014]; [@CD012118-bbs2-0016]; [@CD012118-bbs2-0004]), adverse effects in eight ([@CD012118-bbs2-0013]; [@CD012118-bbs2-0006]; [@CD012118-bbs2-0018]; [@CD012118-bbs2-0002]; [@CD012118-bbs2-0007]; [@CD012118-bbs2-0014]; [@CD012118-bbs2-0016]; [@CD012118-bbs2-0011]), and paradoxical reactions in six studies ([@CD012118-bbs2-0018]; [@CD012118-bbs2-0014]; [@CD012118-bbs2-0015]; [@CD012118-bbs2-0016]; [@CD012118-bbs2-0003]; [@CD012118-bbs2-0011]).

Follow‐up period varied in the RCTs. [@CD012118-bbs2-0009] followed up participants until one year after completion of treatment. In the [@CD012118-bbs2-0005], Nienhuis and colleagues first followed up participants until one year, and then Klis and colleagues revisited participants again during four to six years after treatment. Two trials did not specify their follow‐up time ([@CD012118-bbs2-0010]; [@CD012118-bbs2-0008]). In the earlier study by [@CD012118-bbs2-0017], their follow‐up period ranged from 17 to 40 months, with a median of 32 months. Follow‐up in the prospective observational studies was one year in six studies ([@CD012118-bbs2-0006]; [@CD012118-bbs2-0018]; [@CD012118-bbs2-0014]; [@CD012118-bbs2-0015]; [@CD012118-bbs2-0016]; [@CD012118-bbs2-0011]). Otherwise, it was seven months in [@CD012118-bbs2-0003], 1.5 years in [@CD012118-bbs2-0007], two years in [@CD012118-bbs2-0002] and [@CD012118-bbs2-0012], and not specified in [@CD012118-bbs2-0013], [@CD012118-bbs2-0001], and [@CD012118-bbs2-0004].

### Excluded studies {#CD012118-sec3-0021}

We excluded 475 studies after title and abstract screening. We assessed 75 full‐text articles for eligibility, of which we excluded 37 on the basis of their study design (retrospective observational studies, cross‐sectional surveys, case series, or qualitative studies), eight because they were either reviews or commentaries, five because they were conference proceedings, and four because they were duplicates.

Risk of bias in included studies {#CD012118-sec2-0009}
--------------------------------

We have summarized the risk of bias in included studies in [Figure 2](#CD012118-fig-0002){ref-type="fig"} and [Figure 3](#CD012118-fig-0003){ref-type="fig"}.Figure 2'Risk of bias\' graph: review authors\' judgements about each risk of bias item presented as percentages across all included studies.Figure 3'Risk of bias\' summary: review authors\' judgements about each risk of bias item for each included study.

### Randomized controlled trials {#CD012118-sec3-0022}

Of the five included RCTs, only [@CD012118-bbs2-0005] used adequate methods. Otherwise, either methods were either inadequate or details were poorly reported in the remaining studies.

### Prospective observational studies {#CD012118-sec3-0023}

Of the 13 prospective observational studies, we rated seven recent studies as at low risk of bias ([@CD012118-bbs2-0018]; [@CD012118-bbs2-0002]; [@CD012118-bbs2-0001]; [@CD012118-bbs2-0015]; [@CD012118-bbs2-0016]; [@CD012118-bbs2-0003]; [@CD012118-bbs2-0011]). The older studies were associated with a higher risk of bias ([@CD012118-bbs2-0013]; [@CD012118-bbs2-0006]).

### Allocation {#CD012118-sec3-0024}

Of the five RCTs, two were blinded and were rated as at low risk of bias ([@CD012118-bbs2-0017]; [@CD012118-bbs2-0005]). Otherwise, no information, [@CD012118-bbs2-0008]; [@CD012118-bbs2-0009], or no clear statement, [@CD012118-bbs2-0010], was provided, and these studies were rated as at unclear risk of bias.

### Blinding {#CD012118-sec3-0025}

Of the five RCTs, two were blinded and were rated as at low risk of bias ([@CD012118-bbs2-0017]; [@CD012118-bbs2-0010]). Otherwise, the RCTs were open‐label, [@CD012118-bbs2-0005], or no clear statement was provided, [@CD012118-bbs2-0008]; [@CD012118-bbs2-0009], but were rated as at low risk of bias as the outcome was unlikely to be influenced by lack of blinding.

### Incomplete outcome data {#CD012118-sec3-0026}

Of the five RCTs, we rated one as at high risk of bias, as 10 out of 30 participants (33%) were lost to follow‐up ([@CD012118-bbs2-0008]). The proportion of missing data was relatively large in one RCT (6/18 participants, 33%) ([@CD012118-bbs2-0010]), however reasons for exclusions/missing data were relatively well balanced or unlikely to be related to true outcome, and the RCT was rated as at low risk of bias. Otherwise, no participants, [@CD012118-bbs2-0009], or a minimal number of participants, [@CD012118-bbs2-0017]; [@CD012118-bbs2-0005], were lost to follow‐up, and we judged these RCTs as at low risk of bias.

Of the 13 prospective observational studies, we rated two studies as at high risk of bias: the assessment time point was unclear in [@CD012118-bbs2-0013], and 17 participants were lost to follow‐up during the study period but were included in the final analysis in [@CD012118-bbs2-0006]. Otherwise, either no participants, [@CD012118-bbs2-0012]; [@CD012118-bbs2-0002]; [@CD012118-bbs2-0007]; [@CD012118-bbs2-0014]; [@CD012118-bbs2-0001]; [@CD012118-bbs2-0015]; [@CD012118-bbs2-0004]; [@CD012118-bbs2-0003]; [@CD012118-bbs2-0011], or a minimal number of participants, [@CD012118-bbs2-0018]; [@CD012118-bbs2-0016], were lost to follow‐up, and we considered these studies as at low risk of bias.

### Selective reporting {#CD012118-sec3-0027}

Of the five included RCTs, we rated one as at unclear risk of bias as there were no predefined outcomes ([@CD012118-bbs2-0013]). All of the other RCTs reported all expected outcomes, and we rated these as at low risk of bias.

All 13 prospective observational studies reported all expected outcomes and were rated as at low risk of bias.

### Other potential sources of bias {#CD012118-sec3-0028}

Five studies either did not have laboratory confirmation as their inclusion criteria or only performed laboratory exams in a portion of their participants, therefore non‐Buruli ulcer cases may be included in their study results ([@CD012118-bbs2-0013]; [@CD012118-bbs2-0017]; [@CD012118-bbs2-0008]; [@CD012118-bbs2-0006]; [@CD012118-bbs2-0012]). The standard treatment for Buruli ulcer has transitioned from surgery to drugs plus surgery as adjunctive treatment after the recommendation of drug treatment by the WHO in 2004 ([@CD012118-bbs2-0136]), and this may have created some bias.

Potential comorbidities such as osteomyelitis, HIV/AIDS, diabetes mellitus, cancer, and use of immunosuppressant drugs may have affected some results, especially on severity and healing rate and time. Two studies reported on comorbidities of their study participants: 9.5% in [@CD012118-bbs2-0011] and 16.3% in [@CD012118-bbs2-0014]; there may be an overlap of participants in these two studies.

Effects of interventions {#CD012118-sec2-0010}
------------------------

See: [Table 1](#CD012118-tbl-0001){ref-type="table"}; [Table 2](#CD012118-tbl-0002){ref-type="table"}

We first assess the effects of a variety of treatments on healing and recurrence, stratified by monotherapy and combination therapy. We then summarise adverse effects and paradoxical reactions across all comparisons.

### *Healing and recurrence* {#CD012118-sec3-0029}

#### Monotherapy {#CD012118-sec4-0007}

See [Table 5](#CD012118-tbl-0005){ref-type="table"}.Table 1Monotherapy for treating Buruli ulcer: description of studies and main results**RegimenStudyDesignComparisonsSurgeryInclusion criteria (age, lesion)Laboratory (Y/N)NSex (M:F)AgeLesion typesQuestionOutcome measure and time point (number analysed if different from N)ResultsObservation**CLF[@CD012118-bbs2-0017]RCT2 groups:\
Rx at least until 1 month after complete clinical healing (3 to 6 months)PlaceboWhen indicatedNoneN105NRNRUlcer: 34 (32%)\
Non‐ulcer: 71 (68%)Does CLF reduce recurrence rates?Recurrence8/51 (15.7%)10/54 (18.5%)No obvious effectIs CLF effective?Healed (n = 34)^a^5/13 (38%)6/21 (29%)No obvious effectDoes CLF shorten the healing time?Median healing time (n = 25)^b^21 weeks (n = 8)14 weeks (n = 17)No obvious effectCLF[@CD012118-bbs2-0013]POS1 group: Rx for 1 to 4 weeks followed by surgeryAllNoneN106:4Mean 12.7 (5 to 25)Ulcer: 10 (100%)What is the healing rate for participants treated with CLF and surgery?Healed6/10 (60%)Early study investigating the possible effect of treatment of BU with Rx. Healing rate with CLF plus surgery was 60%. The sample size is too small to draw any conclusion from this study.TMP/SMX[@CD012118-bbs2-0010]RCT2 groups:\
Rx until further excision became necessary (n = 6)Placebo (n = 6)When indicatedNoneY125:7Mean 18.3 (5 to 32)Mean 20.8 (8 to 45)Ulcer: 12 (100%)Is TMP/SMX effective?% change in ulcer size at study end^c,d^‐10.9% (‐26% to ‐6%)24.5% (‐15% to 166%)No obvious effect% covered by granulation tissue at study end92% (70% to 100%)57% (0 to 100%)[^4]

One RCT and one prospective observational study evaluated the efficacy of clofazimine, and one RCT evaluated the efficacy of sulfamethoxazole/trimethoprim. All three studies had small sample sizes, and no treatment effects were demonstrated.

##### Clofazimine {#CD012118-sec5-0003}

[@CD012118-bbs2-0017] compared clofazimine to placebo, with similar recurrence in the two arms (clofazimine 8/51 (15.7%); placebo 10/54 (18.5%); difference 2.8%, 95% confidence interval (CI) not given). The authors examined a subgroup of participants with non‐ulcerated lesions who were withheld from immediate surgery: the number that healed was slightly higher with clofazimine, but the difference was small, and this was a post hoc subgroup analysis (clofazimine, 5/13 (38%); placebo, 6/21 (29%)). The median healing time was measured in this same subgroup also those with a lesion less than 5 cm in diameter (clofazimine, 8 participants; placebo, 17 participants) and was 21 weeks and 14 weeks, respectively.

One prospective observational study, [@CD012118-bbs2-0013], examined the effects of clofazimine with surgery in 10 participants with ulcers. Six participants (60%) achieved complete healing in 3 to 12 weeks. The remaining four participants were still under treatment for their ulcers at the time of reporting.

##### Sulfamethoxazole/trimethoprim {#CD012118-sec5-0004}

[@CD012118-bbs2-0010] compared sulfamethoxazole/trimethoprim to placebo in 12 participants with ulcers. The mean ulcer size in the sulfamethoxazole/trimethoprim group at baseline was 73.8 cm^2^ (9 to 247) and in the placebo group was 38.7 cm^2^ (15 to 80). The authors reported that sulfamethoxazole/trimethoprim reduced ulcer size by an average of 10.9%, while an average increase of 24.5% was observed in the placebo group (P = 0.15). The percentage ulcer area covered by granulation tissue at study end was 92% in the sulfamethoxazole/trimethoprim group and 57% in the placebo group (P = 0.17).

#### Combination therapy {#CD012118-sec4-0008}

##### Rifampicin combined with streptomycin {#CD012118-sec5-0005}

See [Table 6](#CD012118-tbl-0006){ref-type="table"}.Table 2Rifampicin combined with streptomycin for treating Buruli ulcer: description of studies and main results**RegimenStudyDesignComparisonsSurgeryInclusion**\
**(age, lesion)Laboratory (Y/N)NSex**\
**(M:F)AgeLesion typesQuestionOutcome measure and time point**\
**(number analysed if different from N)ResultsOur observation**RFP and SM[@CD012118-bbs2-0009]RCT5 groups: Rx given for 2, 4, 8, 12 weeks prior to surgery versus surgery aloneAll≥ 15 years\
Non‐ulcer\
Size \< 10 cmY217:14NRNodule: 14 (67%)\
Plaque: 7(33%)Does RFP + SM before surgery reduce recurrence?Recurrence, 12 monthsRx + surgery: 0/16\
Surgery alone: 1/5No obvious effectDoes RFP + SM reduce lesion size?Mean surface area reduction in lesion size before and after Rx (n = 16)^a^2 weeks, 5 participants: 29%\
4 weeks, 3 participants: 52%\
8 weeks, 5 participants: 31%\
12 weeks, 3 participants: 41%All tend to get smaller over time. No obvious effect of longer treatmentsRFP and SM[@CD012118-bbs2-0012]POS1 group: Rx for 12 weeksAll (at week 4)3 to 75 years\
Ulcer\
Size \> 10 cmN9243:49\< 15 years: 38 (41%); 15 to 49 years: 43 (47%);\
≥ 50 years: 11 (12%)Ulcer: 92 (100%)Is RFP + SM for 12 weeks with surgery at week 4 effective?Healed with Rx + surgery,\
12 weeks85/92 (92.4%)^b^Surgery plus 12 weeks of Rx associated with high healing and low recurrence at 24 months in large lesions. Independent effect of antibiotics not evaluated.Recurrence,\
24 months2/92 (2.2%)^c^RFP and SM[@CD012118-bbs2-0006]POS1 group: Rx for 8 weeksWhen indicated\
(at week 4, week 8)NoneN224145:79\< 15 years: 179 (58%);\
15 to 49 years: 90 (29%);\
≥ 50 years: 41 (13%)Ulcer: 168 (75%)\
Non‐ulcer: 56 (26%)Does RFP + SM for 8 weeks work?Healed with Rx ± surgery,\
after 8 weeks (n = 206)^d^206/206 (100%)^d^Regimen combined with surgery as needed was associated with high healing rate after 8 weeks and low recurrence at 12 months. 48% of participants healed with Rx alone. 52% required surgery to heal.Healed with Rx alone, after 8 weeks (n = 206)^d^98/206 (48%)^e^Underwent surgery (n = 206)^d^108/206 (52%)^f,g^Healed with Rx + surgery,\
after 8 weeks (n = 108)108/108 (100%)Recurrence, 12 months (n = 208)^h^3/208 (1.4%)^i^RFP and SM[@CD012118-bbs2-0018]POS1 group: Rx for 8 weeksWhen indicated\
(post‐Rx; after week 8)NoneY16066:94Median 12 years\
(1 to 75)Ulcer: 86 (54%)\
Nodule: 36 (22%)\
Plaque: 14 (9%)\
Oedema: 24 (15%)Does RFP + SM for 8 weeks work?Healed with Rx ± surgery,\
12 months (n = 159)^j^158/159 (99.3%)Regimen combined with surgery as needed was associated with high healing rate and low recurrence at 12 months. 95% of participants healed with Rx alone. 5% required surgery to heal.Healed with Rx alone,\
12 months (n = 159)^j^151/159 (95%)Underwent surgery\
(n = 159)^j^8/159 (5%)^k^Healed with Rx + surgery,\
12 months (n = 8)7/8 (87.5%)^l^Recurrence,\
12 months (n = 158)^m^0/158 (0%)RFP and SM[@CD012118-bbs2-0001]POS1 group: Rx for 8 weeksWhen indicated\
(post‐Rx; after week 8)NoneY12664:62Mean 29.8 years\
(1 year 3 months to 98)Ulcer: 116 (92%)\
Papule: 1 (0.5%)\
Nodule: 2(1.5%)\
Oedema: 4(3%)\
Osteo: 2 (1.5%)\
Contracure: 2 (1.5%)Does RFP + SM for 8 weeks work?Healed with Rx alone, 8 weeks61/126 (48%)About half (48%) healed with Rx alone. The other half underwent surgery including excision, skin grafting, and contracture release.RFP and SM[@CD012118-bbs2-0002]POS1 group: Rx for 8 weeksAll\
(during or post‐Rx)NoneY189113:76NRUlcer: 145 (77%)\
Nodule: 38 (20%)\
Plaque: 6 (3%)Does RFP + SM for 8 weeks with surgery work?Healed with Rx + surgery, 2 years^n^182/189 (96.3%)Surgery plus 8 weeks of Rx was associated with high healing rate and low recurrence. Independent effect of Rx not evaluated.Recurrence,\
2 years1/189 (0.5%)RFP and SM[@CD012118-bbs2-0004]POS1 group: Rx for 8 weeksWhen indicated\
(post‐Rx; after week 8)NoneY12960:69Median 10 years\
(2 to 68)Ulcer: 73 (57%)\
Nodule: 19 (15%)\
Plaque: 26 (20%)\
Oedema: 11 (8%)Does RFP + SM for 8 weeks work?Healed with Rx ± surgery,\
\> 6 months109/129 (84.5%)^o^Regimen combined with surgery as needed was associated with relatively high healing rate and no recurrence at minimum 6 months. 70% of participants healed with Rx alone. 27% of participants required surgery, of which 54% healed.Healed with Rx alone,\
\> 6 months90/129 (69.8%)Underwent surgery,\
\> 6 months35/129 (27%)Healed with Rx + surgery,\
6 months (n = 35)19/35 (54%)Recurrence,\
\> 6 monthsNone[^5]

One RCT and six prospective observational studies investigated the efficacy of rifampicin and streptomycin. Five prospective observational studies evaluated this regimen administered for 8 weeks (828 participants) with surgery given to either all participants or a select group. Four studies reported healing rates for all participants, regardless of whether they had received surgery or not (84.5% to 100%, assessed at various time points). Four studies reported healing rates for participants who received combination therapy alone (48% to 95%, assessed at various time points).

One RCT, [@CD012118-bbs2-0009], examined 21 participants with non‐ulcerative lesions to test the efficacy of rifampicin and streptomycin. They divided the participants into 5 groups: 4 groups were given rifampicin and streptomycin for 2, 4, 8, and 12 weeks before surgery respectively, and one group received only surgery. No recurrence was observed in participants in any group receiving combination therapy at 12 months, compared with one case of recurrence in a participant who received only surgery. No difference in recurrence was observed between these two groups (risk ratio (RR) 0.12, 95% CI 0.01 to 2.51; [Figure 4](#CD012118-fig-0004){ref-type="fig"}; [Analysis 1.1](#CD012118-fig-00101){ref-type="fig"}). Reduction in lesion surface area in participants who received rifampicin and streptomycin was the highest (52%) in the group that underwent four weeks of the regimen before surgery.Figure 4Forest plot of comparison: 1 Rifampicin plus streptomycin (experimental) versus surgery alone (control), outcome: 1.1 Recurrence.

One prospective observational study, [@CD012118-bbs2-0012], examined rifampicin and streptomycin given for 12 weeks with surgery performed at week 4, in 92 participants with ulcerative lesions measuring more than 10 cm in diameter. The study showed a high healing rate at week 12 (85/92, 92.4%) and low recurrence rate at 2 years (2/92, 2.2%).

Five prospective observational studies examined treatment with rifampicin and streptomycin for eight weeks ([@CD012118-bbs2-0006]; [@CD012118-bbs2-0018]; [@CD012118-bbs2-0002]; [@CD012118-bbs2-0001]; [@CD012118-bbs2-0004]). In one study all participants received surgery either during or after treatment (in this study surgery included debridement and skin grafting, not just excision) ([@CD012118-bbs2-0002]); in one study a select group received surgery after assessment at week 4 and week 8 ([@CD012118-bbs2-0006]); and in three studies a select group of participants received after eight weeks of treatment ([@CD012118-bbs2-0018]; [@CD012118-bbs2-0001]; [@CD012118-bbs2-0004]).

Where surgery was given to a select group participants, surgery rate differed among studies: 5% in [@CD012118-bbs2-0018], 27% in [@CD012118-bbs2-0004], 52% in [@CD012118-bbs2-0006], and 52% in [@CD012118-bbs2-0001].Four studies reported healing rates for all participants, regardless of whether they received surgery or not: 84.5% in [@CD012118-bbs2-0004], 96.3% in [@CD012118-bbs2-0002], 99.3% in [@CD012118-bbs2-0018] and 100% in [@CD012118-bbs2-0006].Four studies reported healing rates for participants who received combination therapy alone: 48% at week 8 in [@CD012118-bbs2-0001], 48% after week 8 in [@CD012118-bbs2-0006], 69.8% after minimum of 6 months follow‐up in [@CD012118-bbs2-0004], and 95% at 12 months in [@CD012118-bbs2-0018].Follow‐up showed recurrence was unusual: 0% in [@CD012118-bbs2-0018] and [@CD012118-bbs2-0004], 0.5% in [@CD012118-bbs2-0002], and 1.4% in [@CD012118-bbs2-0006].

##### Rifampicin combined with clarithromycin {#CD012118-sec5-0006}

See [Table 7](#CD012118-tbl-0007){ref-type="table"}.Table 3Rifampicin combined with clarithromycin for treating Buruli ulcer: description of studies and main results**RegimenStudyDesignComparisonsSurgeryInclusion (age, lesion)Laboratory (Y/N)NSex**\
**(M:F)AgeLesion typesQuestionOutcome measure and time point (number if different from N)ResultsOur observation**RFP and CAM[@CD012118-bbs2-0007]POS1 group: Rx given for 8 weeksWhen indicated≥ 5 years\
Size ≤ 10 cmY3018:12NRUlcer: 21 (70%)\
Non‐ulcer: 9 (30%)Does 8 weeks of RFP + CAM work?Healed with Rx ± surgery, 12 months30/30 (100%)Regimen combined with surgery as needed was associated with high healing rate at 12 months and no recurrence at 18 months in participants with small lesions. 50% of participants healed with Rx alone. 50% required surgery to heal.Healed with Rx alone, 12 months15/30 (50%)^a^Underwent surgery, 12 months15/30 (50%)Healed with Rx + surgery, 12 months (n = 15)15/15 (100%)^b^Recurrence, 18 monthsNoneRFP and CAM[@CD012118-bbs2-0014]POS1 group: Rx, duration depending upon physician's decisionAllNoneY21NRNRNRDoes RFP + CAM plus surgery work?Healed with Rx + surgery, 12 months21/21 (100%)Surgery plus Rx was associated with high healing rate and no recurrence at 12 months. Independent effect of antibiotics not evaluated. Duration of Rx varied.Recurrence ,\
12 monthsNoneRFP and SM\
*plus*\
RFP and CAM[@CD012118-bbs2-0005]RCT2 groups:\
RFP + SM for 4 weeks (4RS) followed by RFP + CAM for 4 weeks (4RC)RS for 8 weeks (8RS)When indicated≥ 5 years\
Size ≤ 10 cmY15146:105Median 12 years (IQR 9 to 22)Median 12 years (IQR 8 to 18)Ulcer: 59 (39%)\
Non‐ulcer: 92 (61%)Can RFP + CAM substitute for RFP + SM?Healed with Rx alone or Rx + skin grafting, 12 months68/75 (91%)73/76 (96%)^c,d^4RS + 4RC was as effective as 8RS in participants with small lesions. Both regimens were associated with high healing rate and no recurrence at 12 months.Difference in healing timeNone^e^Recurrence,\
12 monthsNoneRFP and SM\
*plus*\
RFP and CAM[@CD012118-bbs2-0016]POS1 group: RFP + SM for 2 weeks (2RS) followed by RFP + CAM for 6 weeks (6RC)When indicated≥ 5 years\
Size ≤ 15 cmY4318:25Median 14 years\
(5 to 70)Ulcer: 20 (47%)\
Nodules: 14 (32%)\
Plaque: 9 (21%)Can RFP + CAM substitute for RFP + SM?Healed with Rx ± surgery, 12 months (n = 41)^f^41/41 (100%)2RS + 6RC combined with surgery as needed was associated with high healing and low recurrence at 12 months in participants with small lesions. 98% of participants healed with Rx alone. 2RS + 6RC may substitute for 8RS, but no definitive conclusion could be made as they were not compared.Healed with Rx alone, 12 months (n = 41)^f^40/41 (98%)Underwent surgery (n = 41)^f^1/41 (2.4%)Healed with Rx + surgery, 12 months (n = 1)1/1 (100%)^g^Recurrence,\
12 months (n = 41)^f^None[^6]

Two prospective observational studies (51 participants) evaluated the use of rifampicin and clarithromycin. Both studies included surgery, either to all participants or a select group. All participants were healed at 12 months.

[@CD012118-bbs2-0007] evaluated rifampicin and clarithromycin for eight weeks in 30 participants with lesions measuring less than 10 cm in diameter. They reported a high healing rate at 12 months with no recurrence at 18 months (30/30, 100%). Half of the participants (50%) healed without any form of surgery; 11 participants (37%) healed with limited surgery including curettage of the lesion or a minor excision; and 4 participants (13%) healed with extensive surgery including major excision followed by skin grafting.

[@CD012118-bbs2-0014] evaluated rifampicin and clarithromycin with surgery in 21 participants and reported a high healing rate (100%) and no recurrence at one year. Duration of the regimen was determined by the attending physician.

##### Rifampicin with streptomycin initially, changing to rifampicin with clarithromycin in consolidation phase {#CD012118-sec5-0007}

See [Table 7](#CD012118-tbl-0007){ref-type="table"}.

One RCT and one prospective observational study examined healing rates starting with rifampicin and streptomycin, and then swapping to rifampicin and clarithromycin, with surgery as indicated. Both studies only included participants with small lesions, and more than 90% of participants healed without surgery.

One RCT, [@CD012118-bbs2-0005], evaluated a regimen of rifampicin plus streptomycin for 4 weeks followed by rifampicin plus clarithromycin for 4 weeks in 151 participants with lesions measuring less than 10 cm in diameter. They compared this to the standard treatment at the time of eight weeks of rifampicin and streptomycin. Both groups achieved high healing rates at 12 months without surgery (a small number in each group had skin grafting): new regimen 68/75 (91%), standard regimen 73/76 (96%). There was no significant difference in healing rate or recurrence between the two groups (RR 0.94, 95% CI 0.87 to 1.03; not estimable due to 0 cases in both groups; [Figure 5](#CD012118-fig-0005){ref-type="fig"}, [Analysis 2.1](#CD012118-fig-00201){ref-type="fig"}; [Figure 6](#CD012118-fig-0006){ref-type="fig"}; [Analysis 2.2](#CD012118-fig-00202){ref-type="fig"}) or in healing time.Figure 5Forest plot of comparison: 2 Rifampicin combined with clarithromycin versus rifampicin combined with streptomycin in the consolidation phase, outcome: 2.1 Cure.Figure 6Forest plot of comparison: 2 Rifampicin plus clarithromycin (experimental) versus rifampicin plus streptomycin in the consolidation phase (control), outcome: 2.2 Recurrence at 12 months.

One prospective observational study, [@CD012118-bbs2-0016], evaluated a regimen of rifampicin plus streptomycin for 2 weeks followed by rifampicin plus clarithromycin for 6 weeks in 43 participants with lesions measuring less than 15 cm in diameter. Forty of 41 (98%) participants achieved healing by 52 weeks without surgery.

##### Novel combination therapy {#CD012118-sec5-0008}

See [Table 8](#CD012118-tbl-0008){ref-type="table"}.Table 4Novel combination regimens for treating Buruli ulcer: description of studies and main results**RegimenStudyDesignComparison(s)SurgeryInclusion**\
**(age, lesion)Laboratory**\
**(Y/N)NSex**\
**(M:F)AgeLesion typesQuestionOutcome measure and time point (number if different from N)ResultsOur observation**RFP and DDS[@CD012118-bbs2-0008]RCT2 groups:\
Rx for 8 weeks (n = 15)Placebo (n = 15)None\> 4 years\
UlcerN3018:12NRUlcer: 30 (100%)Is RFP + DDS effective?Improved after 2 months (n = 28)^a^82% (23/28 points)75% (21/28 points)^b^Unable to assess the effect due to incongruent characteristics at baseline, however there seems to be no obvious effect.Change in ulcer size after 2 months14.0 cm^2^ decrease (range, 3.8 to ‐159.0)2.5 cm^2^ decrease (range, 78.0 to ‐35.0)^c^RFP and either CIPRO, CAM, or MOX[@CD012118-bbs2-0011]POS3 groups:\
RFP + CIPRO (n = 80)RFP + CAM (n = 50)RFP + MOX (n = 2)Limited surgical debridement when indicated^d^\
(extensive surgical excisions excluded)NoneY13275:57Median 49 years (1 to 95)Ulcer: 110 (83.3%)\
Nodule: 9 (6.8%)\
Oedema: 10 (7.6%)\
Plaque: 3 (2.3%)Does RFP‐based all‐oral Rx regimen work?Healed with Rx ± limited surgical debridement,\
12 months131/132 (99%)^e^RFP‐based all‐oral regimens combined with limited surgical debridement as needed were associated with high healing rate and no recurrence at 12 months. 77% of participants healed with Rx alone. Some lesions may need less than 8 weeks of Rx to achieve healing. These were less severe patients, as patients who required extensive surgical excision were excluded. No independent results were given for different regimens.Healed with Rx alone,\
12 months101/132 (76.5%)Median duration of therapy56 days (IQR 24 to 96 days)Duration of therapy: \< 8 weeks22/132 (16.7%)Recurrence,\
12 monthsNoneCombination of RFP, CIPRO, CAM, ETB, MOX, AMK[@CD012118-bbs2-0014]POS2 groups:\
All‐oral Rx (8 different regimens: see below) + surgerySurgery alone\
Regimens:\
RFP + CIPRO (n = 55)RFP + CAM (n = 21)RFP + CAM + ETB (n = 5)CIPRO + CAM (n = 4)RFP + MOX (n = 2)CAM + ETB (n = 1)RFP + ETB + AMK (n = 1)CAM (n = 1)AllNoneY133^f^67:66Median 62 years (3 to 94)Ulcer: 106 (87%)\
Nodules: 9 (7%)\
Oedema: 7 (6%)^f^Is all‐oral Rx treatment plus surgery superior to just surgery?Healed,\
12 months^g^90/90 (100%)33/47 (70%)^h^The tested all‐oral regimen plus surgery was associated with 100% healing and no recurrence at 12 months. 30% of participants who only had surgery had recurrence. Individual effect of Rx not evaluated.Recurrence,\
12 months^g^0/90 (0%)14/47 (30%)^i^[^7]

One RCT and two prospective observational studies investigated the efficacy of combinations of one to three drugs from the following: rifampicin, dapsone, ciprofloxacin, clarithromycin, moxifloxacin, ethambutol, amikacin, and azithromycin. High healing rates and low recurrence were achieved in the two prospective observational studies.

One RCT, [@CD012118-bbs2-0008], examined the efficacy of rifampicin and dapsone for 8 weeks against placebo in 30 participants with ulcerative lesions. No significant differences were observed for clinical improvement as judged by Buruli ulcer specialists using photographs (P = 0.51). A significant change in ulcer size after two months was observed (P = 0.02), however there was a significant difference in the initial ulcer size between the two groups.

Two prospective observational studies from the Australian group tested combinations of one to three oral antibiotics including rifampicin, ciprofloxacin, clarithromycin, moxifloxacin, ethambutol, amikacin, and azithromycin. [@CD012118-bbs2-0011] evaluated participants who received the regimen with no surgery or with limited surgical debridement. Among the 160 participants in their registry, 28 participants (17.5%) who received extensive surgery were excluded, leaving 132 participants for their analysis. They reported that 131/132 (99%) participants healed at one year, among whom 101 (76.5%) participants healed with antibiotics alone. Median duration of antibiotic treatment was 56 days (interquartile range 24 to 96 days), and 22 participants (16.7%) needed fewer than 56 days to reach healing. [@CD012118-bbs2-0014] compared participants who were treated with antibiotics plus surgery to surgery alone. All 90/90 participants (100%) who underwent combined treatment with antibiotics plus surgery healed. Fourteen (30%) participants who received only surgery had recurrence. As the participants were retrieved from the same registry in these two studies, some participants may contribute data to more than one of the studies.

### Adverse effects {#CD012118-sec3-0030}

Three RCTs evaluated adverse effects, of which two reported none ([@CD012118-bbs2-0008]; [@CD012118-bbs2-0009]). One RCT evaluated long‐term adverse effects of streptomycin three to six years after treatment ([@CD012118-bbs2-0005]). Among those that could be retrieved from the past BURULICO study (n = 127), ototoxicity was observed in 23% of adults in the 4‐week streptomycin group and 40% of adults in the 8‐week streptomycin group (total n = 41), and in 28% of children in the 4‐week streptomycin group and 26% of children in the 8‐week streptomycin group (total n = 86). Nephrotoxicity during treatment was observed in 9% of adults in the 4‐week streptomycin group and 20% of adults in the 8‐week streptomycin group, and in 5% of children in the 4‐week streptomycin group and 20% of children in the 8‐week streptomycin group. At long‐term follow‐up, one adult (2.4%) and two children (2.4%) were classified as having long‐term nephrotoxicity, all from the 8‐week streptomycin group.

Eight prospective observational studies evaluated adverse effects, of which two reported none ([@CD012118-bbs2-0006] (rifampicin, streptomycin) and [@CD012118-bbs2-0002] (rifampicin, streptomycin)). One study reported no discontinuation of antibiotics (rifampicin, clarithromycin) due to adverse effects ([@CD012118-bbs2-0007]). [@CD012118-bbs2-0013] reported one participant with gastrointestinal intolerance from clofazimine. [@CD012118-bbs2-0018] reported one participant with dizziness and one with vomiting and dizziness from streptomycin, and one participant with rash probably from rifampicin. [@CD012118-bbs2-0016] reported one participant with ototoxicity from streptomycin. [@CD012118-bbs2-0014] reported that of 90 participants who received antibiotic treatment, 28 (31%) developed adverse effects including gastrointestinal intolerance, hepatitis, rash, hypoglycaemia, joint or tendon effects, palpitations, and hallucinations. [@CD012118-bbs2-0011] reported that 21 of the 132 participants (16%) developed adverse effects (unspecified) that required cessation of one or more antibiotics during treatment.

### Paradoxical reactions {#CD012118-sec3-0031}

See [Table 9](#CD012118-tbl-0009){ref-type="table"}.Table 5Paradoxical reactions in Buruli ulcer: description of studies and main results**RegimenStudyDesignComparisonsSurgeryNSex**\
**(M:F)AgeLesion typesIncidence of PROnset time of PROur observation**RFP and SM[@CD012118-bbs2-0018]POS1 group: RFP + SM for 8 weeks (8RS)When indicated\
(post‐Rx)16066:94Median 12 years\
(1 to 75)Ulcer: 86 (54%)\
Nodule: 36 (22%)\
Plaque: 14 (9%)\
Oedema: 24 (15%)3/159 (1.9%)^a^At weeks 4, 6, 12Approximately 1 in 20 participants treated with 8RS developed PR. 2 cases occurred during Rx and 1 case occurred post‐Rx.RFP and SM\
or\
RFP and SM\
*plus*\
RFP and CAM[@CD012118-bbs2-0003]POS1 group:\
RFP + SM for 8 weeks (n = 166)RFP + SM for 4 weeks followed by RFP + CAM for 4 weeks (n = 75)When indicated24188:153Mean (SD) 16(13) yearsUlcer: 108 (45%)\
Nodule: 32 (13%)\
Plaque: 56 (23%)\
Oedema: 11 (5%)\
Mixed: 34 (14%)52/241 (22%)^b^Between week 8 and 12Approximately 1 in 5 participants treated with Rx developed PR between week 8 and 12.RFP and SM\
*plus*\
RFP and CAM[@CD012118-bbs2-0016]POS1 group: RFP + SM for 2 weeks (2RS) followed by RFP + CAM for 6 weeks (6RC)When indicated4318:25Median 14 years\
(5 to 70)Ulcer: 20 (47%)\
Nodules: 14 (32%)\
Plaque: 9 (21%)4/41 (9.3%)^c^Median 12 weeks (range, 4 to 32 weeks)Approximately 1 in 10 participants treated with 2RS + 6RC developed PR at median 12 weeks after start of treatment.Combination of RFP, CIPRO, CAM, ETB, AMK, MOX[@CD012118-bbs2-0014]POS8 groups: Weeks of\
RFP + CIPRO (n = 55)RFP + CAM (n = 21)RFP + CAM + ETB (n = 5)CIPRO + CAM (n = 4)RFP + MOX (n = 2)CAM + ETB (n = 1)RFP + ETB + AMK (n = 1)CAM (n = 1)All90NRNRNR8/90 (8.9%)^d^Median 48 days (range, 14 to 85 days)Approximately 1 in 10 participants treated with different regimens of Rx developed PR at median 8 weeks after start of treatment.Combination of RFP, CAM, ETB, AMK, MOX[@CD012118-bbs2-0015]POS1 group: received RxWhen indicated15686:70\< 15 years: 13 (8%);\
15 to 60 years: 62 (40%);\
\> 60 years: 81 (52%)Ulcer: 137 (87.8%)\
Nodules: 10 (6.4%)\
Oedema: 9 (5.8%)32/156 (21%)^e^Median 39 days (IQR 20 to 73 days)Approximately 1 in 5 participants treated with different regimens of Rx developed PR at 5.6 weeks after start of treatment.RFP and either CIPRO, CAM, or MOX[@CD012118-bbs2-0011]POS3 groups: Weeks of\
RFP + CIPRO (n = 80)RFP + CAM (n = 50)RFP + MOX (n = 2)Limited surgical debridement when indicated13275:57Median 49 years (1 to 95)Ulcer: 110 (83.3%)\
Nodule: 9 (6.8%)\
Oedema: 10 (7.6%)\
Plaque: 3(2.3%)34/132 (26%)^d^Median 48 days (IQR 29 to 69 days)Approximately 1 in 4 participants treated with different regimens of Rx developed PR at median 8 weeks after start of treatment.[^8]

Six prospective observational studies evaluated paradoxical reactions ([@CD012118-bbs2-0018]; [@CD012118-bbs2-0014]; [@CD012118-bbs2-0015]; [@CD012118-bbs2-0016]; [@CD012118-bbs2-0003]; [@CD012118-bbs2-0011]), of which two studies evaluated solely this outcome ([@CD012118-bbs2-0015]; [@CD012118-bbs2-0003]).

The incidence of paradoxical reactions ranged from 1.9% in [@CD012118-bbs2-0018] to 26% in [@CD012118-bbs2-0011]. Median onset time of paradoxical reactions ranged from 5.6 weeks (39 days) in [@CD012118-bbs2-0015] to 12 weeks in [@CD012118-bbs2-0016]. As the participants were retrieved from the same registry in three studies ([@CD012118-bbs2-0014]; [@CD012118-bbs2-0015]; [@CD012118-bbs2-0011]), some participants may contribute data to more than one of the studies.

Discussion {#CD012118-sec1-0006}
==========

Summary of main results {#CD012118-sec2-0011}
-----------------------

See [Table 1](#CD012118-tbl-0001){ref-type="table"} and [Table 2](#CD012118-tbl-0002){ref-type="table"}.

We included 18 studies, of which five were RCTs, in this review. Earlier studies conducted before 2000 that assessed monotherapy (clofazimine, sulfamethoxazole/trimethoprim) demonstrated no treatment effect. The remaining studies assessed combination therapy with or without surgery. The main regimens included rifampicin plus streptomycin, rifampicin plus clarithromycin, and rifampicin plus streptomycin switching to rifampicin plus clarithromycin during the consolidation phase.

It is evident that antimicrobials are important in treating Buruli ulcers; this was an already established fact, but also learned from this review. Different combinations of antibiotics are given for eight weeks to treat Buruli ulcer, irrespective of the stage. However, there were insufficient studies and data to be able to determine which regimen is the most effective. In 2004, the WHO first recommended a combination of rifampicin and streptomycin for eight weeks ([@CD012118-bbs2-0136]). However, there is no evidence from RCTs to support this treatment. Five prospective observational studies tested this regimen, which reported healing rates from 84.5% to 100% with or without surgery. Four studies reported healing rates for participants who received combination therapy alone to be from 48% to 95%. The time points assessed in the studies varied, and therefore a comparison or calculation of a combined healing rate was not possible.

There has recently been movement from the current regimen, which requires injection, to an all‐oral treatment, with the goal of reducing the burden of treatment for patients. Of the studies included in this review, [@CD012118-bbs2-0005] was the only RCT with adequate methods. This study tested rifampicin plus streptomycin for four weeks followed by rifampicin and clarithromycin for four weeks against rifampicin plus streptomycin for eight weeks, so that the patients will receive fewer injections of streptomycin. The study showed that there was no significant difference in healing rate and time between the two regimens. Other studies have investigated different combinations of oral drugs, with most regimens yielding high healing rates ([@CD012118-bbs2-0007]; [@CD012118-bbs2-0014]; [@CD012118-bbs2-0011]). The study sample sizes were small, and their study design was weak to examine the effects of these regimens, however these studies show the potential of all‐oral treatments. The WHO currently lists use of rifampicin (10 mg/kg once daily) with either streptomycin (15 mg/kg once daily) or clarithromycin (7.5 mg/kg twice daily) for eight weeks as the treatment choices for Buruli ulcer, depending on the patient ([@CD012118-bbs2-0134]; [@CD012118-bbs2-0137]).

When assessing the efficacy of treatments for Buruli ulcers, lesion size, lesion type, and whether surgery was applied or not are important factors to be considered. We attempted to perform a subanalysis, but this was not possible due to the heterogeneity of studies. It may also be important to consider the impact of the severity of lesions (WHO category) on treatment efficacy, however not all studies reported these data. It is important to note that some studies that reported high healing rates recruited only participants with small lesions, which may be important to consider when interpreting the results from these studies ([@CD012118-bbs2-0009]; [@CD012118-bbs2-0005]; [@CD012118-bbs2-0007]; [@CD012118-bbs2-0016]).

Six prospective observational studies measured incidence of paradoxical reactions, which ranged from 1.9% to 26%. The pathogenesis of paradoxical reactions remains unclear, but recent studies report a possible association with antibiotic treatment and types of antibiotics used ([@CD012118-bbs2-0112]; [@CD012118-bbs2-0054]; [@CD012118-bbs2-0015]).

Overall completeness and applicability of evidence {#CD012118-sec2-0012}
--------------------------------------------------

All studies included both males and females. With regards to age, participants from African countries were younger compared to those from Australia, which could have influenced the results. This is reflected by the different age distributions of the affected population between the two areas ([@CD012118-bbs2-0076]; [@CD012118-bbs2-0132]; [@CD012118-bbs2-0077]). Comorbidities (including HIV) in participants were uncommon, or those with comorbidities were excluded from the study, with the exception of the Australia group studies. Rates of comorbidities in the two Australian studies (9.5% and 16.3%) could have affected their study results.

Five studies (26%) diagnosed Buruli ulcer based only on clinical presentation, otherwise all studies had laboratory confirmation of Buruli ulcer either by Ziehl--Neelsen test for AFB, polymerase chain reaction (PCR), or histopathology. All recent studies (after 2007) had laboratory confirmation of Buruli ulcer as part of their inclusion criteria.

Treatment was often given for eight weeks, which has been the WHO recommendation since 2004, and different durations were not tested. Dosages of the drugs were the same between studies: 10 mg/kg/day for rifampicin, 15 mg/kg/day for streptomycin, and 7.5 mg/kg/day for clarithromycin. Intervention with surgery made it a challenge to compare the outcomes between studies. However, it is an important adjunctive intervention to drugs for treating Buruli ulcer, and participants who received surgery were included in the study results. The extent/definition of surgical intervention differed between studies: for example, skin grafting was not considered to be surgery in [@CD012118-bbs2-0005] and [@CD012118-bbs2-0011]. Furthermore, the decision of when to intervene with surgery differs among surgeons/clinicians, and this may have affected the results. It is also important to note that earlier studies tended to perform surgery more often than current studies, as it used to be the standard treatment.

Healing as defined by complete epithelialization was the primary outcome in most studies, but not in the earlier studies, where it was change in ulcer size ([@CD012118-bbs2-0010]; [@CD012118-bbs2-0008]; [@CD012118-bbs2-0009]). The only other outcome that was comparable between studies was recurrence. Assessment time points differed between studies, which made it impossible to compare or synthesize the results from different studies.

### Certainty of the evidence {#CD012118-sec3-0032}

The certainty of the evidence was very low.

Potential biases in the review process {#CD012118-sec2-0013}
--------------------------------------

We attempted to limit bias in the review process. Vittoria Lutje, the Cochrane Infectious Diseases Group Information Specialist, conducted the literature searches, and it is unlikely that these searches missed any major studies; however, we cannot rule out the possibility that we missed some small unpublished studies.

We included prospective observational studies in this review as there was a very limited number of RCTs investigating this topic. This decision was made after a number of discussions between the authors, the Cochrane Infectious Diseases Group, and their reviewers. While this may have created some bias in this review, we have tried to minimize bias by reporting the results of prospective observational studies separately from RCTs.

To limit bias in the study selection process and data extraction, we independently examined the search results, selected studies, and extracted data.

Agreements and disagreements with other studies or reviews {#CD012118-sec2-0014}
----------------------------------------------------------

There were no other studies or reviews with which to compare this review.

Authors\' conclusions {#CD012118-sec1-0007}
=====================

People with Buruli ulcers should receive drug therapy. This is obvious and not the subject of this Cochrane Review.Regarding choice of drug and duration of treatment, the studies included in this review did not provide substantive evidence to guide recommendations. The differences in efficacy between drugs is still uncertain, although the included studies at low risk of bias did demonstrate a high healing rate of Buruli ulcer lesion(s) with the use of combined drug therapy, with or without surgery. How different sizes/lesions/stages of the disease may contribute to healing and which kind of lesions are in need of surgery were unclear from the included studies. These factors need to be considered, as does the practicality of the treatment in resource‐limited settings where most people with Buruli ulcer reside, when guiding recommendations for the treatment of Buruli ulcer.The current available evidence does not support the use of rifampicin and streptomycin for an eight‐week duration, which has been the standard regimen used in endemic African countries.There were two ongoing trials at the time of publication of this Cochrane Review. One trial is a multicentre study between Ghana and Benin testing rifampicin and clarithromycin for eight weeks ([@CD012118-bbs2-0074]). The other trial is testing the timing of surgery with rifampicin and streptomycin for eight weeks ([@CD012118-bbs2-0073]). The preliminary results of these studies were reported at the World Health Organization Buruli Ulcer Meeting in March 2017 and will be included in our updated review.Conducting field trials to test treatment effect of Buruli ulcer is complex and challenging, as:there are a limited number of patients (2000 to 5000 annual cases globally); andthere are multiple treatments that contribute to healing including surgery and wound care and not just drugs.Although we assessed the certainty of the evidence of the studies included in this review as low, researchers have worked hard to generate this body of evidence under these circumstances.Further research will be useful testing different regimens, including the possibility of new drugs/combinations; different durations of treatment depending on the lesion stage; and timing of surgical interventions. Antituberculosis drugs that arrived recently on the market could also be useful in the treatment of Buruli ulcer and need to be tested, yet the high cost of these drugs is a concern for use in resource‐limited settings, where most patients reside. Cost analysis of treatment ‐ which is often neglected and needs more attention ‐ is therefore also an important area for investigation. As Buruli ulcer is a toxic disease while it is an infection, antitoxins or other systemic drugs may bring about a breakthrough in the treatment of the disease and are interesting areas for exploration. The development of reliable and low‐cost point‐of‐care diagnostic tools are needed to promote a better body of evidence for Buruli ulcer treatment. The primary diagnostics to confirm the disease is currently polymerase chain reaction (PCR), which is not readily available in many endemic areas. Assessment time points of healing and recurrence should be made uniform so as to allow comparison between studies, and such action should be initiated. This can be facilitated by the development of tools to quantify healing. For example, level of mycolactone in lesions, blood, or urine could be a candidate for this purpose in the future when quantitative test of mycolactone will be made easier to use. Wound care is another essential focus for research in Buruli ulcer, which may also benefit other diseases with ulcers. Operational research in order to detect, diagnose, and treat patients early also needs to be promoted.

Marty Richardson is supported by the Research, Evidence and Development Initiative (READ‐It) project. The READ‐It project and the editorial base of the Cochrane Infectious Diseases Group are funded by UK aid from the UK government for the benefit of low‐ and middle‐income countries (project number 300342‐104). The views expressed do not necessarily reflect the UK government's official policies.

**Search setCIDG SR^1^CENTRALMEDLINEEmbaseLILACS**1Buruli ulcer\*\"Buruli Ulcer\"\[Mesh\] OR \"Mycobacterium ulcerans\"\[Mesh\]\"Buruli Ulcer\"\[Mesh\] OR \"Mycobacterium ulcerans\"\[Mesh\]Buruli ulcer (Emtree) OR Buruli ulcer\* ti, abBuruli ulcer\*2Mycobacterium ulceransBuruli ulcer\* ti, abBuruli ulcer\* ti, abMycobacterium ulcerans \[Emtree\]Mycobacterium ulcerans31 or 2Buruli AND skin ti, abBuruli AND skin ti, abBuruli AND skin ti, ab1 or 24---1 or 2 or 3\"Mycobacterial skin ulcer\*\" or \"mycobacterium skin ulcer\*\" ti, ab\"Mycobacterial skin ulcer\*\" or \"mycobacterium skin ulcer\*\" ti, ab---5------1 or 2 or 3 or 41 or 2 or 3 or 4---6------randomized controlled trial.pt. OR controlled clinical trial.pt.Clinical trial or Randomized controlled trial or Randomization or Single blind procedure or Double blind procedure or Crossover procedure or Placebo OR prospective study \[Emtree\]---7------\"Prospective Studies\"\[Mesh\]Randomi?ed controlled trial\*.tw.---8------randomized.ab. or placebo.ab.Random or randomly. Ti, ab---9------randomly.ab. or trial.ab.\
or groups.ab.Placebo\* ti, ab---10------treatment OR therap\* ti, abtreatment OR therap\* ti, ab---11------6 or 7 or 8 or 9 or 106 or 7 or 8 or 9 or 10---12------5 and 115 and 11---

^1^Cochrane Infectious Diseases Group Specialized Register.

Comparison 1Rifampicin combined with streptomycin versus surgery aloneOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Recurrence](#CD012118-fig-00101){ref-type="fig"}Analysis 1.1Comparison 1 Rifampicin combined with streptomycin versus surgery alone, Outcome 1 Recurrence.121Risk Ratio (M‐H, Fixed, 95% CI)0.12 \[0.01, 2.51\]

Comparison 2Rifampicin combined with clarithromycin versus rifampicin combined with streptomycin in the consolidation phaseOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Cure](#CD012118-fig-00201){ref-type="fig"}Analysis 2.1Comparison 2 Rifampicin combined with clarithromycin versus rifampicin combined with streptomycin in the consolidation phase, Outcome 1 Cure.1151Risk Ratio (M‐H, Fixed, 95% CI)0.94 \[0.87, 1.03\][2 Recurrence at 12 months](#CD012118-fig-00202){ref-type="fig"}Analysis 2.2Comparison 2 Rifampicin combined with clarithromycin versus rifampicin combined with streptomycin in the consolidation phase, Outcome 2 Recurrence at 12 months.1151Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\]

We did not include the planned methods for conducting meta‐analyses in the review due to the small number of included studies and their heterogeneity.

We added paradoxical reactions to the [Secondary outcomes](#CD012118-sec4-0002){ref-type="sec"}.

We revised the 'Risk of bias\' assessment. The method stated in the protocol was only applicable to randomized controlled trials and not to prospective observational studies.

We added the following search terms: 'Buruli and skin\', 'mycobacterial skin ulcer\*\', and 'mycobacterium skin ulcer\*\'.

Characteristics of included studies \[ordered by study ID\] {#CD012118-sec2-0018}
===========================================================

[@CD012118-bbs2-0001]MethodsProspective observational studyParticipantsInclusion criteria: clinically + laboratory‐confirmed BU (exclusion: none stated)\
Laboratory confirmation: either by ZN test for acid‐fast bacilli (AFB), PCR, or histopathology\
Enrolled: 126 participants\
Participant characteristics: 64 males, 50.8%; mean age 29.8 (range, 1 year 3 months to 98 years)\
Lesion types: ulcer 116 (92%), papule 1 (0.5%), nodule 2 (1.5%), oedema 4 (3%), chronic osteomyelitis 2 (1.5%), contractures 2 (1.5%) (1 participant with both ulcer and contracture)\
WHO category I: 12 (10%), category II: 43 (34%), category III: 71 (56%)InterventionsRifampicin (10 mg/kg/day) + streptomycin (15 mg/kg/day), 8 weeks, with surgery\
Surgery: when indicated after antibiotic treatment\
Follow‐up: N/AOutcomes\"Healed without surgery\", assessed at 8 weeks\
**Standardized outcome: possible cure**NotesTrial location: Ghana\
Enrolment dates: January 2010 to December 2012\
The primary objective of the study was to document the complications of BU and the reconstructive surgery performed in patients whose lesions were not completely healed after 8 weeks of antibiotic treatment.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (Trials)High risk---Allocation concealment (Trials)High risk---Blinding of participants and personnel (Trials)High risk---Blinding of outcome assessment (Trials)High risk---Selection of participants into the study (Prospective observational studies)Low riskSelection not related to intervention or outcome.Measurement of outcomes (Prospective observational studies)Low riskObjective outcome measure (healing)Incomplete outcome data / missing data (All studies)Low riskNo missing dataSelective reporting (All studies)Low riskReported all expected outcomesOther biasLow riskNo other bias identified.[@CD012118-bbs2-0002]MethodsProspective observational studyParticipantsInclusion criteria: clinically + laboratory‐confirmed BU (exclusion: none stated)\
Laboratory confirmation: any 2 positives of ZN test for AFB, PCR, and histopathology\
Enrolled: 189 participants\
Participant characteristics: 113 males, 60%; age N/A\
Lesion types: ulcer 145 (76.7%), nodule 38 (20.1%), plaque 6 (3.2%)\
WHO category I: 44 (22.3%), categories II + III: 145 (76.7%)InterventionsRifampicin (10 mg/kg/d) + streptomycin (15 mg/kg/d), 8 weeks, with surgery\
Surgery: all cases\
Follow‐up: 2 years after discharge from hospitalOutcomesHealing rateRecurrenceAdverse effectsMean hospital stay daysNumber of new BU cases and their disease stage at the study site after counselling and health education activities\
**Standardized outcome: cure**NotesTrial location: Ghana\
Enrolment dates: January 2005 to December 2005***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (Trials)High risk---Allocation concealment (Trials)High risk---Blinding of participants and personnel (Trials)High risk---Blinding of outcome assessment (Trials)High risk---Selection of participants into the study (Prospective observational studies)Low riskSelection not related to intervention or outcome.Measurement of outcomes (Prospective observational studies)Low riskObjective outcome measure (healing)Incomplete outcome data / missing data (All studies)Low risk3 participants (3.2%) were lost to follow‐up but for different outcomes.Selective reporting (All studies)Low riskReported all expected outcomesOther biasLow riskNo other bias identified.[@CD012118-bbs2-0003]MethodsProspective observational studyParticipantsInclusion and exclusion criteria: refer to [@CD012118-bbs2-0005] and [@CD012118-bbs2-0073]\
Enrolled: 241 participants; 150 from [@CD012118-bbs2-0005] and 91 from [@CD012118-bbs2-0073]\
Participant characteristics: 88 (37%) males, mean (SD) 16.2 (13.2) years\
Lesion types: ulcer 108 (45%), nodule 32 (13%), plaque 56 (23%), oedema 11 (5%), mixed 34 (14%)\
WHO category I: 69 (29%), category II: 133 (55%), category III: 39 (16%)InterventionsRefer to [@CD012118-bbs2-0005] and [@CD012118-bbs2-0073]OutcomesParadoxical reaction defined by an initial decrease of the lesion size followed by 2 consecutive increasesNotesTrial location: Ghana and Benin\
Enrolment dates: [@CD012118-bbs2-0005], 2006 to 2008; [@CD012118-bbs2-0073], 2011 to 2015***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (Trials)High risk---Allocation concealment (Trials)High risk---Blinding of participants and personnel (Trials)High risk---Blinding of outcome assessment (Trials)High risk---Selection of participants into the study (Prospective observational studies)Low riskSelection not related to intervention or outcome.Measurement of outcomes (Prospective observational studies)Low riskObjective outcomes clearly defined.Incomplete outcome data / missing data (All studies)Low riskNo loss to follow‐upSelective reporting (All studies)Low riskReported all expected outcomesOther biasHigh riskParadoxical reaction was only defined clinically by lesion size; no exams to support diagnosis.[@CD012118-bbs2-0004]MethodsProspective observational studyParticipantsInclusion criteria: clinically + laboratory‐confirmed BU; any age (exclusion: laboratory‐unconfirmed cases)\
Laboratory confirmation: IS2404 dry‐reagent‐based PCR\
Enrolled: 199 eligible participants; 70 dropouts (35.2%); 129 participants analysed\
Participant characteristics: 60 males, 46.5%; median 10 years, range 2 to 68 years\
Lesion types: ulcer 73 (76.7%), nodule 19 (14.7%), plaque 26 (20.2%), oedema 11 (8.5%)\
WHO category I: 59 (45.7%), category II: 44 (34.1%), category III: 26 (20.2%)InterventionsRifampicin (10 mg/kg/d) + streptomycin (15 mg/kg/d), 8 weeks\
Surgery: when indicated\
Follow‐up: follow‐up visits were conducted January to April 2013 (110 participants) and May to June 2014 (19 participants) (\> 6 months elapsed since the end of antimicrobial treatment).OutcomesHealed with or without surgeryHealing timeSecondary lesionsFunctional limitationsRecurrence until the follow‐up visit\
**Standardized outcome: possible cure**NotesTrial location: Togo\
Enrolment dates: September 2007 to November 2013***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (Trials)High risk---Allocation concealment (Trials)High risk---Blinding of participants and personnel (Trials)High risk---Blinding of outcome assessment (Trials)High risk---Selection of participants into the study (Prospective observational studies)High riskOnly 129 out of 199 eligible patients could be retrieved and enrolled.Measurement of outcomes (Prospective observational studies)Low riskObjective outcome measure (healing)Incomplete outcome data / missing data (All studies)Low riskNo missing dataSelective reporting (All studies)Low riskReported all expected outcomesOther biasLow riskNo other bias identified.[@CD012118-bbs2-0005]MethodsRandomized controlled trialParticipantsInclusion criteria: clinically + laboratory‐confirmed BU; aged 5 years or older, had a reported disease duration of less than 6 months, and had lesions with a cross‐sectional diameter (indurated area) of 10 cm or less (exclusions: pregnancy, drug intolerance, and renal, hepatic, and acoustic impairment)\
Laboratory confirmation: IS2404 dry‐reagent‐based PCR\
Enrolled: 151 participants; 143 with infection confirmed by PCR, 5 with infection confirmed by other methods, 3 cases were clinical diagnosis\
Participant characteristics: intervention group 19 (25%) males, median 12 years (IQR 9 to 22); control group 27 (36%) males, median 12 years (IQR 8 to 18)\
Lesion types: ulcer 59 (39.1%), non‐ulcer 92 (60.9%)\
WHO category I: 58 (38.4%), category II + III: 93 (61.16%)InterventionsRifampicin (10 mg/kg/day) + streptomycin (15 mg/kg/day), 4 weeks followed by rifampicin (10 mg/kg/day) + clarithromycin (7.5 mg/kg/day), 4 weeksRifampicin (10 mg/kg/day) + streptomycin (15 mg/kg/day), 8 weeks\
Surgery: when indicated\
Follow‐up: once a week participants were given study drugs to take to the nearest health facility to receive directly observed treatment for the subsequent days, with daily wound care. Participants with complicated lesions were hospitalized.\
Participants were followed up at weekly intervals during the first 8 weeks; at week 10, week 12, and then monthly to week 36, and bimonthly to week 52. Study visits included clinical assessment with reporting of adverse effects, measurement of lesion size (if not healed) by tracing onto an acetate sheet, and photography of the lesion.OutcomesHealed without surgery or recurrence (cure)Cumulative proportion of healingDifference in healing time between the 2 groupsSkin graftsRecurrenceFunctional impairmentAdverse effects (ototoxicity, nephrotoxicity, abdominal discomfort) during treatmentLong‐term adverse effects (ototoxicity, nephrotoxicity) ([@CD012118-bbs2-0100])NotesTrial location: Ghana\
Enrolment dates: April 2006 to January 2008\
HIV antibody testing was done with cold‐stored sera after completion of the study, in which 3 (2%) participants were found positive.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (Trials)Low riskComputer‐generated minimizationAllocation concealment (Trials)Low riskAssigned allocation was sent from a central site by text message to study co‐ordinator.Blinding of participants and personnel (Trials)Low riskOpen‐label, but outcome unlikely to be affected by participant knowledge of treatment group.Blinding of outcome assessment (Trials)Low riskOpen‐label, but primary endpoint also assessed by blinded wound experts, and the results concurred with those from the primary analysis.Selection of participants into the study (Prospective observational studies)Unclear risk---Measurement of outcomes (Prospective observational studies)Unclear risk---Incomplete outcome data / missing data (All studies)Low risk4 participants withdrew/died/were lost to follow‐up but were still included in analysis for primary endpoint as the lesion had healed at the last assessment.Selective reporting (All studies)Low riskReported all expected outcomesOther biasLow risk3 cases not laboratory‐confirmed, but only a small number.[@CD012118-bbs2-0006]MethodsProspective observational studyParticipantsInclusion criteria: clinical diagnosis of BU; residing in an endemic area\
(exclusion criteria: pregnancy; receiving traditional treatment at the time of diagnosis; history of leprosy, TB; liver, kidney, or hearing problems)\
Enrolled: 310 participants; 36 immediate surgical excision at another centre, 3 pregnancy, 47 refusals; 224 analysed\
Participant characteristics: among the 310 eligible participants, 145 males, 47%; \< 15 years, 179 participants (58%), 15 to 49 years, 90 participants (29%), ≥ 50 years, 41 participants (13%)\
Lesion types: ulcer 168 (73.8%), of which 29 (18.4%) were \< 5 cm, 76 (48.1%) were 4 to 14 cm, and 63 (39.9%) were ≥ 10 cm; non‐ulcer 56 (26.2%)\
WHO category: N/AInterventions8 weeks of rifampicin (10 mg/kg/day) + streptomycin (15 mg/kg/day) was administered to all participants. During the 4‐week assessment, participants who were considered unlikely to be cured by antibiotics alone (opinion of the treating physician) underwent surgery.\
Local dressings were provided for participants with ulcerative lesions. Participants were treated daily under the direct observation of the clinic nurse either as an outpatient or inpatient. The study physician evaluated participants every 2 weeks during treatment.\
Surgery: when indicated\
Follow‐up period: 1 year after treatment completionOutcomesSuccessful treatment: completely healedRecurrence: reactivation of the disease within 1 year after apparent success upon treatment completion\
**Standardized outcome: probable cure**NotesTrial location: Benin\
Enrolment dates: January 2003 to December 2004***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (Trials)High risk---Allocation concealment (Trials)High risk---Blinding of participants and personnel (Trials)High risk---Blinding of outcome assessment (Trials)High risk---Selection of participants into the study (Prospective observational studies)High risk86/310 patients (28%) who were eligible for the study were not included; 3 pregnancies, 36 immediate surgical excisions at another centre, 6 participants\' decision to receive traditional treatment, 41 refusals of antibiotic and/or surgical treatment.Measurement of outcomes (Prospective observational studies)Low riskObjective outcome measure (healing)Incomplete outcome data / missing data (All studies)High riskWe do not have data for 17 participants who were lost to follow‐up at week 8.Selective reporting (All studies)Low riskReported all expected outcomesOther biasHigh riskLaboratory exam was attempted in 145 of the 168 participants. 40/145 (28%) were negative for both PCR and smear, indicating that some cases may not have been BU.[@CD012118-bbs2-0007]MethodsProspective observational studyParticipantsInclusion criteria: clinically + laboratory‐confirmed BU; at least 5 years of age, presented with lesions ≤ 10 cm in diameter that had appeared within the past 6 months, agreed to be hospitalized during treatment, and were likely to be followed up for 18 months\
(exclusion criteria: multiple lesions, lesions located over a joint, history of treatment with antimycobacterial drugs, receipt of macrolide or quinolone antibiotics during the previous month, allergy to rifampicin or clarithromycin, pregnancy, or HIV infection)\
Laboratory confirmation: IS2404 dry‐reagent‐based PCR\
Enrolled: 30 participants for analysis\
Participant characteristics: 12 males, 40%; 11 were \> 15 years of age\
Lesion types: ulcer 21 (47%), non‐ulcer 9 (30%)\
WHO category I: 13 (43%), category II: 17 (57%)InterventionsRifampicin (10 mg/kg/d) + clarithromycin (12 mg/kg/d), 8 weeks\
Surgery: when indicated\
Follow‐up: participants were hospitalized during treatment for daily direct observation by nursing staff and were examined by a doctor every week. Swabs or aspiration samples were collected at week 4, 6, 8 if the lesion had not healed for culture and PCR. Participants were discharged from hospital when healed and were followed up every 3 months up to 18 months after start of treatment.OutcomesWound healing at 12 months, without recurrence 18 months after initiation of antibioticsNeed of additional care to antibiotics (limited surgery, excision and skin grafting)\
**Standarized outcome: cure**NotesTrial location: Benin\
Enrolment dates: December 2007 to February 2009***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (Trials)High risk---Allocation concealment (Trials)High risk---Blinding of participants and personnel (Trials)High risk---Blinding of outcome assessment (Trials)High risk---Selection of participants into the study (Prospective observational studies)High risk2/3 of eligible population refused participation due to refusal of hospitalization.Measurement of outcomes (Prospective observational studies)Low riskObjective outcome measure (healing)Incomplete outcome data / missing data (All studies)Low riskNo missing dataSelective reporting (All studies)Low riskReported all expected outcomesOther biasLow riskNo other bias identified.[@CD012118-bbs2-0008]MethodsRandomized controlled trialParticipantsInclusion criteria: clinical diagnosis of BU\*; aged 4 years or older (excluded: history of TB, leprosy, HIV, liver disease, pregnancy, breastfeeding)\
Case definition: the presence of a painless or minimally painful cutaneous ulcer with undermined margins\
Enrolled: 41 participants; 10 participants were lost to follow‐up, 1 pregnancy: 30 participants for analysis\
Participant characteristics: intervention group 11 (73%) males, median 13 years old (range, 5 to 60); control group 7 (47%) males, median 10 years old (range, 5 to 60)\
Lesion types: ulcer 30 (100%)\
WHO category: N/AInterventionsDapsone (1.0 to 1.5 mg/kg/day) + rifampicin (10 to 20 mg/kg/day), 2 monthsPlacebo identical in appearance to dapsone, 2 months\
Both groups received supportive local ulcer care consisting of cleansing and non‐surgical debridement.\
Surgery: none\
Follow‐up: 2 months; photographs were taken at enrolment and at 2 months for 28 participantsOutcomesClinical change, judged by photographs as \"worse\", \"unchanged\", or \"improved\", by 2 specialists blinded to groupChange in ulcer sizeAdverse effectsNotesTrial location: Côte d\'Ivoire\
Enrolment dates: 3 March to 4 April 1994\
\*Diagnostic tests: not all cases were confirmed as BU: 6/41 (14.6%) skin biopsies were diagnostic of BU (containing AFB or active necrosis of adipose tissue); 29 (70.7%) were indicative of BU (granulomatous changes and necrosis, without AFB); the remaining 3 revealed non‐specific inflammation; 3/41 (7%) yielded positive cultures.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (Trials)Low riskQuote: \"Participants were randomized by lot to one of two groups.\"Allocation concealment (Trials)Unclear riskNo information on allocation concealmentBlinding of participants and personnel (Trials)Low riskIt does not seem that participants were blinded fully, as the placebo participants received only 1 pill, whereas the treatment group participants received 2 pills. Investigators were also not blinded. However, outcome is probably unlikely to be influenced by lack of blinding.Blinding of outcome assessment (Trials)High riskInvestigators not blinded to treatment status, and outcome is likely to have been affected by lack of blinding.Selection of participants into the study (Prospective observational studies)Unclear risk---Measurement of outcomes (Prospective observational studies)Unclear risk---Incomplete outcome data / missing data (All studies)High risk10 participants were lost to follow‐up with no reasons provided. Given this study\'s sample size, this is a relatively large amount of missing data. The numbers in each group were initially balanced across treatment and placebo groups.Selective reporting (All studies)Low riskReported all expected outcomesOther biasHigh riskThere is a big difference in initial median ulcer size between treatment and placebo groups.\
Photography outcome is prone to subjectivity.\
A total of 41 skin biopsies from 30 enrolled participants were taken. 3/30 (10%) yielded no specific change compatible to BU, indicating these cases may not be BU.[@CD012118-bbs2-0009]MethodsRandomized controlled trialParticipantsInclusion criteria: clinically + laboratory‐confirmed BU; had a single nodule or plaque ≤ 10 cm in maximum diameter; aged 15 years or older (exclusion criteria: pregnancy, treatment with antibiotics, history of leprosy, TB, liver, kidney, or hearing problems)\
Laboratory confirmation: either 1 or 2\
Culture (+) or definite histopathology (the presence of Buruli‐type coagulative necrosis of the dermis or subcuticular issue, with or without granulomas, and with or without AFB)PCR (+) plus possible histopathology (the presence of panniculitis, with or without granulomas but without Buruli‐type coagulative necrosis) or visible AFB\
Enrolled: 33 participants; 1 participant withdrew, 1 excluded, 1 resolved completely during treatment, 9 participants did not meet final laboratory diagnosis; 21 participants for analysis\
Participant characteristics: 7 male, 33%; mean age N/A\
Lesion types: 14 nodules, 7 plaques\
WHO category: N/AInterventions5‐arm study comparing immediate excision of the lesion and closure of the wound (no antibiotic), rifampicin (10 mg/kg/d) + streptomycin (15 mg/kg/d) given for 4 weeks, 8 weeks, 12 weeks before excision of the lesion.\
Additional arm added during the study of rifampicin (10 mg/kg/d) + streptomycin (15 mg/kg/d), 2 weeks before excision of the lesion.\
All participants were admitted to hospital for directly observed therapy.\
Surgery: all cases\
Follow‐up period: 12 months after surgeryOutcomesChange in mean surface areas of lesions before and after treatment with antibiotics for 2, 4, 8, or 12 weeksRecurrenceAdverse effectsNotesTrial location: Ghana\
Enrolment dates: September 2001 to December 2002***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (Trials)High riskParticipants in 4 groups (4 week, 8 week, 12 week, and surgery only) were randomized using computer‐generated numbers. Participants in 2 week treatment group were recruited sequentially and were not randomized.Allocation concealment (Trials)Unclear riskNo information on allocation concealmentBlinding of participants and personnel (Trials)Low riskBlinding was not possible given different lengths of treatment and surgical intervention, however outcome is unlikely to be influenced by lack of blinding.Blinding of outcome assessment (Trials)Unclear riskNo information on blinding of assessors, and outcome may be affected by lack of blindingSelection of participants into the study (Prospective observational studies)Unclear risk---Measurement of outcomes (Prospective observational studies)Unclear risk---Incomplete outcome data / missing data (All studies)Low riskAll 21 participants eligible for analysis in the study were analysed.Selective reporting (All studies)Low riskReported all expected outcomesOther biasLow riskNo other bias identified.[@CD012118-bbs2-0010]MethodsRandomized controlled trialParticipantsInclusion criteria: clinically + laboratory‐confirmed BU (exclusion criteria: none stated)\
Laboratory confirmation: diagnosis of BU was confirmed by ZN staining in 6 participants, culture in 4 participants, and histopathology in the remaining participants.\
Enrolled: 18 participants; 6 excluded from analysis due to lost to follow‐up (4) and death (2); 12 participants for analysis\
Participant characteristics: 5 male, 42%; sulfamethoxazole/trimethoprim group: 18.3 years (5 to 32), placebo: 20.8 years (8 to 45)\
Lesion types: ulcer 12/12 (100%)\
4/6 (66%) in the sulfamethoxazole/trimethoprim and 2/6 (33%) in the placebo group received surgery prior to intervention.Initial ulcer size was 73.8 (9 to 247) cm^2^ for the sulfamethoxazole/trimethoprim and 38.7 (15 to 80) cm^2^ for the placebo group.InterventionsSulfamethoxazole/trimethoprim (800 mg sulfamethoxazole/160 mg trimethoprim) 1 tablet twice daily for participants above 12 years; 0.5 tablet twice daily for younger participantsIdentical placebo\
Surgery: when indicated\
Follow‐up: follow‐up was done by standardized examination including photographic documentation of ulcer size by the same observer up to 5 times in approximately 2‐weekly intervals.OutcomesPercentage change of ulcer size\* at study endPercentage covered by granulation tissue at study endExcision during follow‐up\
\*Ulcer size: calculated by multiplying the greatest width by the greatest depth in centimetres\
The study was concluded whenever further excision became necessary during follow‐up.NotesTrial location: Ghana\
Enrolment dates: February to June 1988***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (Trials)High riskUsed alternate allocation methodAllocation concealment (Trials)Unclear riskUnclear statement: \"Patients were, in double‐blinded fashion, alternately allocated to Batrium forte or identical placebo.\"Blinding of participants and personnel (Trials)Low riskIdentical placebo was used.Blinding of outcome assessment (Trials)Unclear riskNot explicitly stated that the outcome assessor was blinded, though outcome was assessed by 1 individual.Selection of participants into the study (Prospective observational studies)Unclear risk---Measurement of outcomes (Prospective observational studies)Unclear risk---Incomplete outcome data / missing data (All studies)Low riskProportion of missing data is relatively large considering the sample size. However, reasons for exclusions/missing data are relatively well balanced or unlikely to be related to true outcome.Selective reporting (All studies)Low riskReported all expected outcomesOther biasHigh riskBaseline characteristics are not well balanced. No significant differences, but the groups are so small the P values would not detect significant differences.[@CD012118-bbs2-0011]MethodsProspective observational studyParticipantsInclusion criteria: clinically + laboratory confirmed; treated with antimicrobials alone or with limited surgical debridement\* (excluded: those who underwent extensive surgery\*\*)\
\*Curettage of the lesion or a minor excision to remove excess granulation tissue and to debride ulcer margins, with or without use of a split skin graft\
\*\*Complete excision of the entire lesion including margins of non‐necrotic tissue, with either direct closure or the use of a split skin graft or a vascularized skin and tissue flap for reconstruction or to cover the defect\
Laboratory confirmation: any of (1) a culture of *Mycobacterium ulcerans* from the lesion, (2) PCR(+), or (3) histopathology showing a necrotic granulomatous ulcer with the presence of AFB\
Enrolled: 160 participants; 28 underwent extensive surgery and were excluded; 132 participants for analysis\
Participant characteristics: 75 males, 56.8%; median age 49 years (range, 1 to 95)\
Lesion types: ulcer 110 (83.3%), nodule 9 (6.8%), oedema 10 (7.6%), plaque 3 (2.3%)\
WHO category I: 104 (78.8%), category II: 19 (14.4%), category III: 9 (6.8%)InterventionsAntibiotics alone or antibiotics with limited surgical debridement\
Included regimens:\
Rifampicin (10 mg/kg/d) plus\
Ciprofloxacin (500 mg twice daily)Clarithromycin (500 mg twice daily; 7.5 to 15 mg/kg/daily in divided doses in children)Moxifloxacin (400 mg daily**)**\
Surgery: when indicated\
Follow‐up: 12 monthsOutcomesTreatment success defined as complete healing of the *M ulcerans* lesion without recurrence within 12 months of treatment commencement **(cure)**RecurrenceTreatment failureAdverse effectsParadoxical reactionsDuration of antibiotic administrationNotesTrial location: Australia\
Enrolment dates: 1 October 2010 to 31 December 2014\
13/132 participants (9.5%) had diabetes mellitus.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (Trials)High risk---Allocation concealment (Trials)High risk---Blinding of participants and personnel (Trials)High risk---Blinding of outcome assessment (Trials)High risk---Selection of participants into the study (Prospective observational studies)Low riskAll patients who met the study inclusion criteria were included.Measurement of outcomes (Prospective observational studies)Low riskObjective outcome measure (healing)Incomplete outcome data / missing data (All studies)Low riskNo missing dataSelective reporting (All studies)Low riskReported all expected outcomesOther biasUnclear risk9.5% of participants had comorbidities that may have affected healing rate and time.[@CD012118-bbs2-0012]MethodsProspective observational studyParticipantsInclusion criteria: clinically diagnosed BU; ulcerative lesions with maximum diameter ≥ 10 cm; 3 to 75 years old; residence in an endemic area (exclusion criteria: previous treatment by rifampicin or streptomycin; previous diagnosis of leprosy or TB; pregnancy; presence of cardiovascular, hepatic, or renal disease)\
Enrolled: 94 participants; 1 refusal, 1 lost to follow‐up; 92 participants for analysis\
Participant characteristics: 43 males, 47%; 38 participants ≤ 15 years, 43 participants 15 to 49 years, 11 participants ≥ 50 years\
Lesion types: ulcer 92 participants (100%)\
WHO category II: 90 participants (97.8%), category III: 2 participants (2.2%)InterventionsRifampicin (10 mg/kg/d) + streptomycin (15 mg/kg/d) for 12 weeks, with surgery after the first 4 weeks\
Local treatment was applied daily with an aqueous solution of chloramine‐metronidazole‐nitrofurandoine.\
Surgery: all cases\
Follow‐up period: follow‐up evaluation was carried out at the end of the 4th and 12th week of treatment. Recurrence was followed up for at least 2 years after treatment completion.OutcomesClinical outcome: \"success\" (4th week: 10% to 30% reduction in ulcer size and/or absence of new necrotic tissue, 12th week: healed), \"clinical status quo\" (no change in the size or presence of necrotic tissue), or \"failure\" (increase in the size and presence of new necrotic tissue)Recurrence: reappearance of an ulcer or another form of the disease (nodule, papule, plaque, oedema, or bone involvement) at the original site of the lesion or elsewhere\
**Standardized outcome: cure**NotesTrial location: Democratic Republic of Congo\
Enrolment dates: October 2006 to September 2007\
Clinical outcome was compared between PCR(+) and PCR(‐) participants.\
PCR(+): 61 participants\
PCR(‐): 31 participants***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (Trials)High risk---Allocation concealment (Trials)High risk---Blinding of participants and personnel (Trials)High risk---Blinding of outcome assessment (Trials)High risk---Selection of participants into the study (Prospective observational studies)Low riskSelection not related to intervention or outcome.Measurement of outcomes (Prospective observational studies)Low riskObjective outcome measure (healing)Incomplete outcome data / missing data (All studies)Low risk1 lost to follow‐up, 1 deathSelective reporting (All studies)Low riskReported all expected outcomesOther biasHigh riskPCR‐negative cases (30 participants, 33%) may not be BU.[@CD012118-bbs2-0013]MethodsProspective observational studyParticipantsInclusion criteria: individuals with proved mycobacterial ulceration who presented themselves for treatment (exclusion criteria: none stated)\
Enrolled: 10 participants\
Participant characteristics: 6 males, 60%; median age 12.7 years (range, 6 to 20)\
Lesion type: ulcers 10/10 (100%)\
WHO category: N/AInterventionsB.663 (riminophenazine derivative; currently, clofazimine) was given as part of preparation for operation for 1 to 4 weeks and continued after operation until healing.\
Adults \> 50 kg: 300 mg/day\
Adults 25 to 50 kg, children: 200 mg/day\
Surgery: all cases\
Follow‐up: not specifiedOutcomesHealing\
**Standarized outcome: possible cure**NotesTrial location: Uganda\
Enrolment dates: none stated.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (Trials)High risk---Allocation concealment (Trials)High risk---Blinding of participants and personnel (Trials)High risk---Blinding of outcome assessment (Trials)High risk---Selection of participants into the study (Prospective observational studies)Low riskSelection not related to intervention or outcome.Measurement of outcomes (Prospective observational studies)Low riskObjective outcome measure (healing)Incomplete outcome data / missing data (All studies)Unclear riskNot clear at what time point participants were assessed and whether they had data for all 10 participants at a given time pointSelective reporting (All studies)Unclear riskNo predefined outcomesOther biasUnclear riskNo laboratory confirmation[@CD012118-bbs2-0014]MethodsProspective observational studyParticipantsInclusion criteria: clinically + laboratory‐confirmed BU; managed with surgery (exclusion criteria: none stated)\
Laboratory confirmation: any of (1) a culture of *Mycobacterium ulcerans* from the lesion, (2) PCR(+), or (3) histopathology showing a necrotic granulomatous ulcer with the presence of AFB.\
Enrolled: 147 participants; 1 without surgery, 2 deaths, 1 lost to follow‐up, 10 ongoing treatment were excluded; 137 lesions of 133 participants analysed\
Participant characteristics: 67 males, 50.4%; median age 62 years (range, 3 to 94)\
Lesion types: clinical type of lesion was recorded in 122/133 participants (92%); ulcer 106 (87%), nodules 9 (7%), oedematous lesion 7 (6%).\
WHO classification: N/AInterventionsSurgery with or without different oral antibiotic treatments\
90 participants received antibiotics as follows.\
Rifampicin + ciprofloxacin (55 participants, 61%)Rifampicin + clarithromycin (21 participants, 23%)Rifampicin + clarithromycin, and ethambutol (5 participants, 4%)Ciprofloxacin + clarithromycin (4 participants, 4%)Rifampicin + moxifloxacin (2 participants, 2%)Clarithromycin + ethambutol (1 participant, 1%)Rifampicin + ethambutol, and amikacin (1 participant, 1%)Clarithromycin only (1 participant, 1%)\
Drug dosages:\
Rifamipicin 10 mg/kg/day (up to a maximum of 600 mg/day)Ciprofloxacin 500 mg twice dailyClarithromycin 500 mg twice dailyMoxifloxacin 400 mg dailyAmikacin 15 mg/kg/dayEthambutol not given\
Surgery: all cases\
Follow‐up: 12 monthsOutcomesTreatment success, defined as complete healing of the *M ulcerans* lesion without recurrence within 12 months of treatment commencement **(cure)**RecurrenceAntibiotic duration prior to surgeryAdverse effectsParadoxical reactionsNotesTrial location: Australia\
Enrolment dates: March 1998 to May 2010\
11 participants were complicated with diabetes mellitus, 5 with malignancy, 4 with connective tissue disease, and 4 with immunosuppressive treatment.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (Trials)High risk---Allocation concealment (Trials)High risk---Blinding of participants and personnel (Trials)High risk---Blinding of outcome assessment (Trials)High risk---Selection of participants into the study (Prospective observational studies)High riskSmall numbers lost to follow‐up, but 10 were excluded because treatment was ongoing, therefore selection related to outcome present.Measurement of outcomes (Prospective observational studies)Low riskOutcomes were objective.Incomplete outcome data / missing data (All studies)Low riskNo missing dataSelective reporting (All studies)Low riskReported all expected outcomesOther biasHigh riskThe proportion of participants receiving antibiotic treatment increased from 2005; there might be important differences between groups especially before this time. Study not really able to detect differences between treatment + surgery and surgery alone. 24/133 (18%) of participants had comorbidities that may have affected healing.[@CD012118-bbs2-0015]MethodsProspective observational studyParticipantsInclusion criteria: clinically + laboratory‐confirmed BU; received antibiotics with or without surgery (exclusion criteria: none stated)\
Laboratory confirmation: any of (1) a culture of *Mycobacterium ulcerans* from the lesion, (2) PCR(+), or (3) histopathology showing a necrotic granulomatous ulcer with the presence of AFB\
Enrolled: 160 participants; 2 deaths, 2 lost to follow‐up; 156 participants analysed\
Participant characteristics: 86 males, 55.1%; 13 participants (8.3%) \< 15 years, 62 participants (39.7%) 15 to 59 years, 81 participants (51.9%) \> 60 years\
Lesion types: ulcer 137 (87.8%), nodules 10 (6.4%), oedematous lesion 9 (5.8%)\
WHO classification: N/AInterventionsDifferent oral antibiotic treatments.\
Participants received combinations of the following.\
Rifampicin 147 (94.2%)Ciprofloxacin 101 (64.7%)Clarithromycin 48 (30.8%)Ethambutol 11 (7.1%)Amikacin 5 (3.2%)Moxifloxacin 2 (1.5%)\
Drug dosages\
Rifamipicin 10 mg/kg/day (up to a maximum of 600 mg/day)Ciprofloxacin 500 mg twice dailyClarithromycin 7.5 mg/kg/twice daily (up to maximum of 500 mg twice daily)Moxifloxacin 400 mg dailyAmikacin 15 mg/kg/day\
Surgery: when indicated\
Follow‐up: at least 12 monthsOutcomesEpisodes of paradoxical reactionsLesion siteDiagnosis and treatmentHealing of paradoxical reactionsPredictors of paradoxical reactionsNotesTrial location: Australia\
Enrolment dates: 1 January 1998 to 31 December 2011\
13 (8.3%) participants were complicated with diabetes mellitus and 11 (7.1%) with immune suppression (defined as current treatment with immunosuppressive medication (for example, prednisolone) or an active malignancy).***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (Trials)High risk---Allocation concealment (Trials)High risk---Blinding of participants and personnel (Trials)High risk---Blinding of outcome assessment (Trials)High risk---Selection of participants into the study (Prospective observational studies)Low riskSmall number (4) not included as did not have 12 months follow‐up or had died.Measurement of outcomes (Prospective observational studies)Low riskParadoxical reaction clearly defined.Incomplete outcome data / missing data (All studies)Low riskNo missing dataSelective reporting (All studies)Low riskReported all expected outcomesOther biasLow riskNo other bias identified.[@CD012118-bbs2-0016]MethodsProspective observational studyParticipantsInclusion criteria: clinically + laboratory‐confirmed BU; at least 5 years of age, presented with lesions ≤ 15 cm in diameter\
(exclusion criteria: tuberculosis or leprosy; renal or hepatic impairment, auditory problems; under treatment with antibiotics or herbal preparations; pregnancy)\
Laboratory confirmation: IS2404 dry‐reagent‐based PCR\
Enrolled: 82 patients screened for BU; 17 not meeting clinical and or epidemiological criteria for BU, 18 large category III lesions, 1 pregnancy, 3 were below 5 years; 43 for analysis\
Participant characteristics: 18 males, 42%; median age 15 (range, 5 to 70)\
Lesion types: ulcer 20 (47%), nodules 14 (32%), plaque 9 (21%)\
WHO category I: 27 (63%), category II: 12 (28%), category III: 4 (9%)InterventionsRifampicin (10 mg/kg/d) + streptomycin (15 mg/kg/d), 2 weeks followed by rifampicin (10 mg/kg/d) + clarithromycin (7.5 mg/kg/d), 6 weeks\
The treatment was administered under the direct observation of village health workers.\
Surgery: when indicated; surgery and skin grafting was offered to participants whose lesion had enlarged during or after treatment by more than 150% of the initial size or had not healed by week 52.\
Follow‐up: 52 weeksOutcomesHealing of the *Mycobacterium ulcerans* lesion without recurrence within 12 months of treatment commencement **(cure)**Healing timeRecurrenceAdverse event (vestibulocochlear toxicity)Paradoxical reactionsNotesTrial location: Ghana\
Enrolment dates: July 2009 to July 2010***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (Trials)High risk---Allocation concealment (Trials)High risk---Blinding of participants and personnel (Trials)High risk---Blinding of outcome assessment (Trials)High risk---Selection of participants into the study (Prospective observational studies)Low riskSelection not related to intervention or outcome.Measurement of outcomes (Prospective observational studies)Low riskObjective outcome measuresIncomplete outcome data / missing data (All studies)Low riskOnly 2 (5%) participants were lost to follow‐up.Selective reporting (All studies)Low riskReported all expected outcomesOther biasLow riskNo other bias identified.[@CD012118-bbs2-0017]MethodsRandomized controlled trialParticipantsInclusion criteria: clinically diagnosed BU (exclusion criteria: none stated)\
Laboratory confirmation: 22/105 (21%) participants had positive cultures for *Mycobacterium ulcerans*.\
Enrolled: 106 participants; 1 excluded; 105 participants for analysis\
Participant characteristics: sex N/A; age N/A\
Lesion types: ulcer 34/105 (33%)\
WHO category: N/AInterventionsParticipants were placed into 4 groups:\
uncomplicated non‐ulcerated lesions with immediate surgery withheld (Group A: 34 participants, 32.5%);uncomplicated non‐ulcerated lesions with immediate surgery (Group B: 16 participants, 15%);complicated non‐ulcerated lesions with immediate surgery (Group C: 21 participants, 20%);ulcerated lesion with immediate surgery (Group D: 34 participants, 32.5%).\
They were randomized to the following groups.\
Clofazimine (10 to 20 mg/kg/day) continued for at least 1 month after complete clinical healing (3 to 6 months)Placebo capsule\
Surgery: when indicated\
Follow‐up: participants were followed up every 2 weeks at a clinic in the trial area. Those who did not attend were visited at home. After the treatment period, participants were seen at approximately 3‐monthly intervals. The follow‐up period ranged from 17 to 40 months (median of 32 months).OutcomesHealingMedian healing timeRecurrence\
**Standarized outcome: possible cure**NotesTrial location: Uganda\
Enrolment dates: July 1968 to March 1970***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (Trials)High riskOnly partial group was randomized.Allocation concealment (Trials)Low riskAllocation concealed from both participant and doctor.Blinding of participants and personnel (Trials)Low riskPlacebo capsule was used, and both participant and doctor were blinded.Blinding of outcome assessment (Trials)Unclear riskNo information about whether outcome assessors were blindedSelection of participants into the study (Prospective observational studies)Unclear risk---Measurement of outcomes (Prospective observational studies)Unclear risk---Incomplete outcome data / missing data (All studies)Low riskOnly 1 participant missing, and reason explained and unlikely to affect outcome.Selective reporting (All studies)Low riskReported all expected outcomesOther biasLow riskNo other bias identified.[@CD012118-bbs2-0018]MethodsProspective observational studyParticipantsInclusion criteria: clinically + laboratory‐confirmed BU (exclusion criteria: previous diagnosis of leprosy or TB; presence of renal or hepatic impairment or auditory problems; treatment with antibiotics or herbal preparations)\
Laboratory confirmation: diagnosis was confirmed by 1 or more methods. Swabs, punch biopsy specimen, or fine‐needle aspirates were taken to test for the following.\
AFBCulture for *Mycobacterium ulcerans*PCR for IS2404\
Enrolled: 171 participants; 6 participants with no diagnostic samples, 5 participants with negative laboratory results; 160 participants for analysis\
Participant characteristics: 66 males (41%), median 12 years (range, 1 to 75 years)\
Lesion types: ulcer 86 (53.7%), nodule 36 (22.5%), plaque 14 (8.8%), oedema 24 (15%)\
WHO category I: 48 (30%), category II: 56 (35%), category III: 56 (35%)InterventionsRifampicin (10 mg/kg/d) + streptomycin (15 mg/kg/d) for 8 weeks\
Surgery: when indicated\
Follow‐up period: 1 year after treatment completionOutcomesHealing of the *M ulcerans* lesion without recurrence within 12 months of treatment commencement **(cure)**Healing timeRate of healing of each measurable lesionRecurrence until 12 monthsAdverse effectsParadoxical reactionsNotes**Trial location:** Ghana\
**Enrolment dates:** September 2005 to December 2007***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (Trials)High risk---Allocation concealment (Trials)High risk---Blinding of participants and personnel (Trials)High risk---Blinding of outcome assessment (Trials)High risk---Selection of participants into the study (Prospective observational studies)Low riskSelection not related to intervention or outcome.Measurement of outcomes (Prospective observational studies)Low riskObjective outcome measuresIncomplete outcome data / missing data (All studies)Low risk1 death and 1 lost to follow‐up at 1 yearSelective reporting (All studies)Low riskReported all expected outcomesOther biasLow riskNo other bias identified.[^9]

Characteristics of excluded studies \[ordered by study ID\] {#CD012118-sec2-0019}
===========================================================

StudyReason for exclusion[@CD012118-bbs2-0019]Conference proceeding[@CD012118-bbs2-0020]Wrong study design[@CD012118-bbs2-0021]Review[@CD012118-bbs2-0022]Wrong study design[@CD012118-bbs2-0023]Wrong study design[@CD012118-bbs2-0024]Wrong study design[@CD012118-bbs2-0025]Wrong study design[@CD012118-bbs2-0026]Duplicate[@CD012118-bbs2-0027]Review[@CD012118-bbs2-0028]Conference proceeding[@CD012118-bbs2-0029]Wrong outcomes[@CD012118-bbs2-0030]Review[@CD012118-bbs2-0031]Wrong study design[@CD012118-bbs2-0032]Wrong study design[@CD012118-bbs2-0033]Wrong study design[@CD012118-bbs2-0034]Wrong study design[@CD012118-bbs2-0035]Wrong study design[@CD012118-bbs2-0037]Wrong study design[@CD012118-bbs2-0036]Wrong study design[@CD012118-bbs2-0038]Wrong intervention[@CD012118-bbs2-0039]Wrong study design[@CD012118-bbs2-0040]Wrong study design[@CD012118-bbs2-0041]Wrong study design[@CD012118-bbs2-0042]Wrong study design[@CD012118-bbs2-0043]Wrong study design[@CD012118-bbs2-0044]Duplicate[@CD012118-bbs2-0045]Commentary[@CD012118-bbs2-0046]Duplicate[@CD012118-bbs2-0047]Commentary[@CD012118-bbs2-0048]Wrong study design[@CD012118-bbs2-0049]Conference proceeding[@CD012118-bbs2-0050]Review[@CD012118-bbs2-0051]Wrong study design[@CD012118-bbs2-0052]Commentary[@CD012118-bbs2-0053]Wrong outcomes[@CD012118-bbs2-0054]Duplicate[@CD012118-bbs2-0055]Wrong intervention[@CD012118-bbs2-0056]Wrong study design[@CD012118-bbs2-0057]Conference proceeding[@CD012118-bbs2-0058]Wrong study design[@CD012118-bbs2-0059]Wrong study design[@CD012118-bbs2-0060]Wrong intervention[@CD012118-bbs2-0061]Commentary[@CD012118-bbs2-0062]Wrong study design[@CD012118-bbs2-0063]Wrong intervention[@CD012118-bbs2-0064]Wrong study design[@CD012118-bbs2-0065]Wrong study design[@CD012118-bbs2-0066]Wrong setting[@CD012118-bbs2-0067]Wrong study design[@CD012118-bbs2-0068]Wrong study design[@CD012118-bbs2-0069]Wrong study design[@CD012118-bbs2-0070]Wrong study design[@CD012118-bbs2-0071]Wrong intervention[@CD012118-bbs2-0072]Conference proceeding

Characteristics of ongoing studies \[ordered by study ID\] {#CD012118-sec2-0020}
==========================================================

[@CD012118-bbs2-0073]Trial name or titleTiming of surgical intervention in Buruli ulcer patients treated with antibiotics (Burulitime)MethodsRandomized controlled trial (single‐blind)ParticipantsInclusion criteria: aged 3 years and older, all stages of the BU disease with confirmation by direct microscopy following acid‐fast staining or PCR\
Exclusion criteria: patients not on the standard treatment of 8 weeks of rifampicin and streptomycin for any reason, including non‐compliant patients; treatment with macrolide or quinolone antibiotics, or antituberculous medication, or immunomodulatory drugs including corticosteroids within the previous 1 month; contraindication for general anaesthesia; pregnancy; osteomyelitis; lesion close to the eye; refusal to surgery at any point in the intended treatment; HIV positive; lack of willingness to give informed consent\
Estimated enrolment: 260InterventionsRifampicin (10 mg/kg/d) + streptomycin (15 mg/kg/d), 8 weeks plus surgery at week 8Rifampicin (10 mg/kg/d) + streptomycin (15 mg/kg/d), 8 weeks plus surgery at week 14OutcomesPrimary outcome\
Healing without surgical intervention (time frame: 1 year)\
Secondary outcomes\
Extent of surgery by measurement of lesional sizeFunctional limitations after the end of treatment and 1 year after the start of treatmentDuration of admissionStarting dateSeptember 2011\
Anticipated end date: January 2017Contact informationYmkje Stienstra, MD PhD, University Medical Center GroningenNotesTrial location: Benin\
Registration number: NCT01432925[@CD012118-bbs2-0074]Trial name or titleRandomized controlled trial comparing efficacy of 8 weeks treatment with clarithromycin and rifampicin versus streptomycin and rifampicin for Buruli ulcer (*Mycobacterium ulcerans* infection)MethodsRandomized controlled trial (multicentre, open‐label)ParticipantsInclusion criteria: aged 5 years and older, with a clinical diagnosis of BU disease (categories I and II, cross‐sectional diameter ≤ 10 cm) as agreed by study site treatment team led by the lead clinicians\
Exclusion criteria: lesion sizes \> 10 cm in cross‐sectional diameter; children \< 5 years, or \< 20 kg body weight; pregnancy; previous treatment of Buruli ulcer, tuberculosis, or leprosy with at least 1 of the study drugs (rifampicin, streptomycin, clarithromycin); history of hypersensitivity to rifampicin and/or streptomycin and/or clarithromycin; previous treatment with macrolide or quinolone antibiotics, or antituberculosis medication, or immunomodulatory drugs including corticosteroids within 1 month; current treatment with any drugs likely to interact with the study medication; co‐infection with HIV; history or having current clinical signs of ascites, jaundice, partial or complete deafness, myasthenia gravis, renal dysfunction (known or suspected), diabetes mellitus, and severe immune compromise (for example, immunosuppressive drugs after organ transplant), or evidence of (previous) tuberculosis, Buruli ulcer or leprosy, or terminal illness (for example, metastasized cancer); unable to take oral medication or having gastrointestinal disease likely to interfere with drug absorption; individuals with known or suspected bowel strictures who cannot tolerate macrolide antibiotics such as clarithromycin; mental condition likely to interfere with ability to comply with the study protocol\
Estimated enrolment: 415InterventionsRifampicin (10 mg/kg/d) + streptomycin (15 mg/kg/d), 8 weeksRifampicin (10 mg/kg/d) + clarithromycin (7.5 mg/kg/d), 8 weeksOutcomesPrimary outcome\
Healing without recurrence and without excision surgery (time frame: 12 months after start of treatment)\
Secondary outcomes\
Recurrence rate within 12 months of treatment initiationNumber of recurrent lesions occurring after initial healing within 12 months of treatment initiationRate of treatment failure within 12 months of treatment initiationRate of paradoxical response within 12 months of treatment initiationProportion of participants with reduction in lesion surface area within 12 months of treatment initiationTime taken for complete lesion healing within 12 months of treatment initiationProportion (%) of participants with complete healing without additional surgery or relapseInterval between healing and recurrenceProportion of each type of surgery within 12 months of treatment initiationTime from treatment initiation to surgery if anyProportion of participants with residual functional limitationsTreatment discontinuation and compliance ratesIncidence of all adverse effects within 12 months of treatment initiationStarting dateDecember 2012\
Anticipated end date: January 2018Contact informationTjip S van der Werf, Professor, University Medical Center Groningen (t.s.van.der.werf\@umcg.nl)NotesTrial location: 1 centre in Benin and 4 centres in Ghana\
Registration number: NCT01659437[^10]

Rie Roselyne Yotsu conceived the review question, extracted and analysed data, and co‐ordinated and drafted the protocol and review. Marty Richardson extracted and analysed data, provided statistical advice, and edited the protocol and review. Norihisa Ishii supervised the clinical content and approved the final version prior to submission.
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Liverpool School of Tropical Medicine, UK.

External sources {#CD012118-sec2-0017}
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The Japan Agency for Medical Research and Development, Japan.Material support for field research on leprosy/Buruli ulcer in Cote d\'Ivoire (18jm0510004h0001)The Sasakawa Memorial Health Foundation, Japan.Material support for field research on leprosy/Buruli ulcer in Cote d\'IvoireDepartment for International Development, UK.Project number 300342‐104
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[^1]: Editorial Group: Cochrane Infectious Diseases Group.

[^2]: ^a^Downgraded by 1 for risk of bias: study small and not concealed. ^b^Downgraded by 2 for imprecision: very few events and wide CIs.

[^3]: ^a^Cure is defined as \"healing of skin lesions without recurrence at 12 months or longer.\" There were no recurrences in this study. ^b^Downgraded by 2 for imprecision: very few events and wide CIs.

[^4]: ^a^Healing was measured in 34 participants with non‐ulcerated lesions who were withheld from immediate surgery. ^b^Healing time was measured in 25 participants with non‐ulcerated lesions who were withheld from surgery and had small lesions (\< 5 cm in diameter). ^c^4 participants in group 1 and 2 participants in group 2 had surgery prior to intervention. ^d^Initial mean ulcer size: (1) 73.8 cm^2^ (9 to 247), (2) 38.7 cm^2^ (15 to 80).

    Abbreviations: CLF, clofazimine; TMP/SMX, sulfamethoxazole/trimethoprim; Lab, laboratory confirmation; NR, not reported; POS, prospective observational study; RCT, randomized controlled trial; Rx, treatment.

[^5]: ^a^16 participants who received Rx plus surgery were analysed. Participant characteristics for this group were: M:F = 6:10; age: NR; lesion types: nodule, 11 (69%), plaque, 5 (31%). ^b^PCR(+) group, 60/61 (98.4%); PCR(‐) group, 25/30 (83.3%). ^c^2/61(3.3%) among PCR(+) group. ^d^17 lost to follow‐up; 1 death. ^e^Ulcer size \< 5 cm, 22/98 (22.5%); ulcer size 5 to 14 cm, 40/98 (41%); ulcer size \>= 15 cm, 12/98 (12%); non‐ulcer, 24/98 (24.5%). ^f^Ulcer size \< 5 cm, 5/108 (4.6%); ulcer size 5 to 14 cm, 27/108 (25%); ulcer size \>= 15 cm, 46/108 (42.6%); non‐ulcer, 30/108 (27.8%). ^g^Decision to perform surgery was made by a treating physician: immediate upon enrolment, 4/108 (3.7%); 4‐week assessment, 83/108 (76.9%); 8‐week assessment, 21/108 (19.4%). ^h^208 participants were retrieved for 1‐year follow‐up. ^i^2 among the Rx‐only group; 1 among the Rx + surgery group. ^j^1 death. ^k^2 participants with nodules, 1 participant with plaque, 5 participants with ulcerated oedematous lesions, and 2 participants with large ulcers were offered surgical intervention after 8 weeks of Rx; 8 accepted surgery. ^l^1 participant evaluated as treatment failure in this review although successful treatment at 1 year follow‐up. The participant received additional 4 weeks of RFP + SM (a total of 12 weeks) with breaking down of skin grafting with culture positive during course of treatment. ^m^158 participants were retrieved for 1‐year follow‐up after treatment completion. ^n^Debridement and skin grafting included as surgery: 38 participants (20.1%) with nodules or plaque excised, 151 participants with ulcers (79.9%) had debridement and skin grafting. ^o^5 participants (3.9%) had secondary lesions, and 15 participants (11.6%) had functional limitations.

    Abbreviations: Lab, laboratory confirmation; NR, not reported; Osteo, osteomyelitis; POS, prospective observational study; RCT, randomized controlled trial; RFP, rifampicin; Rx, treatment; SM, streptomycin.

[^6]: ^a^8/10 (80%) with ulcerative‐WHO category I lesion; 5/11 (45%) with ulcerative‐WHO category II lesion; 2/3 (66%) with non‐ulcerative‐WHO category I lesion; 0/6 (0%) with non‐ulcerative‐WHO category II lesion. ^b^11 (37%) with limited surgery; 4 (13%) with excision and skin grafting. ^c^Skin grafting without excision: (1) 1/75 (1.3%); (2) 4/76 (5.3%). ^d^Odds ratio 2.49, 95% confidence interval 0.66 to infinity; P = 0.16, 1‐sided Fisher's exact test. ^e^Group proportional hazard model: P = 0.26; 99% confidence interval 0.22 to 0.29; generalized Wilcoxon‐Mann‐Whitney test: P = 0.60; 99% confidence interval 0.56 to 0.64. ^f^2 lost to follow‐up. ^g^Skin grafting at week 32.

    Abbreviations: CAM, clarithromycin; IQR, interquartile range; Lab, laboratory confirmation; NR, not reported; POS, prospective observational study; RCT, randomized controlled trial; RFP, rifampicin; Rx, treatment; SM, streptomycin.

[^7]: ^a^Judged by 2 Buruli ulcer specialists using photographs taken at enrolment and at 2 months. Photographs were available for 14 participants from each group; each evaluator's score was counted as 1 point. ^b^P = 0.51. ^c^P = 0.02; however, the initial median ulcer size was bigger in the treatment group than in the placebo group (26.2 cm^2^ (0.25 to 280) versus 4.8 cm^2^ (0.25 to 57.5), P = 0.04). ^d^Limited surgical debridement was defined as curettage of the lesion or a minor excision to remove excess granulation tissue and to debride ulcer margins, with or without the use of a split skin graft. ^e^Results not available for each individual regimen. ^f^Clinical type of lesion was recorded in 122/133 participants (92%). ^g^137 lesions were analysed. ^h^P \< 0.001. ^i^Median time of recurrence: 90 days (range, 14 to 300 days).

    Abbreviations: AMK, amikacin; DDS, dapsone; CAM, clarithromycin; CIPRO, ciprofloxacin; ETB, ethambutol; IQR, interquartile range; Lab, laboratory confirmation; MOX, moxifloxacin; NR, not reported; POS, prospective observational study; RCT, randomized controlled trial; RFP, rifampicin; Rx, treatment; SM, streptomycin.

[^8]: ^a^One death. ^b^37/166 (22%) received RFP + CIPRO; 15/75 (20%) received RFP + CAM. ^c^2 participants lost to follow‐up. ^d^Results not available for each individual regimen. ^e^Predictors of paradoxical reactions (multivariable analysis): age ≥ 60 years (risk ratio (RR) 2.84, 95% confidence interval (CI) 1.12 to 7.17; P = 0.03), oedematous lesion (RR 3.44, 95% CI 1.11 to 10.70; P = 0.03), use of amikacin in the initial Rx regimen (RR 6.33, 95% CI 2.09 to 19.18; P \< 0.01).

    Abbreviations: AMK, amikacin; CAM, clarithromycin; CIPRO, ciprofloxacin; ETB, ethambutol; IQR, interquartile range; Lab, laboratory confirmation; MOX, moxifloxacin; NR, not reported; POS, prospective observational study; PR, paradoxical reactions; RCT, randomized controlled trial; RFP, rifampicin; Rx, treatment; SD, standard deviation; SM, streptomycin.

[^9]: Abbreviations: AFB: acid‐fast bacilli; BU: Buruli ulcer; IQR: interquartile range; N/A: not available; PCR: polymerase chain reaction; SD: standard deviation; TB: tuberculosis; WHO: World Health Organization; ZN: Ziehl‐Neelsen.

[^10]: Abbreviations: BU: Buruli ulcer; PCR: polymerase chain reaction
